Review article

Molecular insights into the multifunctional role of natural compounds: autophagy modulation and cancer prevention

Md. Ataur Rahman^{1, 2, 3*}, MD. Hasanur Rahman^{3, 4}, Md. Shahadat Hossain^{3, 5}, Partha Biswas^{3, 6}, Rokibul Islam^{2, 7}, Md Jamal Uddin^{3, 8}, Md. Habibur Rahman⁹, Hyewhon Rhim^{1, 10*}

¹Center for Neuroscience, Korea Institute of Science and Technology (KIST), Seoul, Republic of Korea.

²Global Biotechnology & Biomedical Research Network (GBBRN), Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia 7003, Bangladesh.

³ABEx Bio-Research Center, East Azampur, Dhaka-1230, Bangladesh.

⁴Department of Biotechnology and Genetic Engineering, Bangabandhu Sheikh Mujibur Rahman Science and Technology University, Gopalganj-8100, Bangladesh.

⁵Department of Biotechnology and Genetic Engineering, Noakhali Science and Technology University, Noakhali, Bangladesh.

⁶Department of Genetic Engineering and Biotechnology, Jashore University of Science and Technology, Jashore, Bangladesh.

⁷Department of Biotechnology and Genetic Engineering, Faculty of Biological Sciences, Islamic University, Kushtia, Bangladesh.

⁸Graduate School of Pharmaceutical Sciences, College of Pharmacy, Ewha Womans University, Seoul 03760, Republic of Korea.

⁹Department of Global Medical Science, Wonju College of Medicine, Yonsei University, South Korea.

¹⁰Division of Bio-Medical Science and Technology, KIST School, Korea University of Science and Technology (UST), Seoul 02792, Republic of Korea.

***Correspondence should be addressed to:** Center for Neuroscience, Brain Science Institute, Korea Institute of Science and Technology (KIST), 5 Hwarang-ro 14-gil, Seongbuk-gu, Seoul 02792, Republic of Korea. Tel.: +82-2-958-5923, Fax: +82-2- 958-6937. Md. Ataur Rahman, E-mail: ataur1981rahman@hotmail.com Hyewhon Rhim, E-mail: hrhim@kist.re.kr

Abstract

Autophagy is a vacuolar, lysosomal degradation pathway for injured and damaged protein molecules and organelles in eukaryotic cells, which is controlled by nutrients and stress responses. Dysregulation of cellular autophagy may lead to various diseases such as neurodegenerative disease, obesity, cardiovascular disease, diabetes, and malignancy. Recently, natural compounds have come to attention for being able to modulate the autophagy pathway in cancer prevention, although the prospective role of autophagy in cancer treatment is very complex and not yet clearly elucidated. Numerous synthetic chemicals have been identified that modulate autophagy and are favorable candidates for cancer treatment, but they have adverse side effects. Therefore, different phytochemicals, which include natural compounds and their derivatives, have attracted significant attention for use as autophagy modulators in cancer treatment with minimal side effects. In the current review, we discuss the promising role of natural compounds in modulating the autophagy pathway to control and prevent cancer, and provide possible therapeutic options.

Keywords: Autophagy, cancer, phytochemical, natural compound, treatment.

1. Introduction

Autophagy is triggered by the entrapment of abnormal intracellular proteins, invading microorganisms, and damaged organelles with the formation of double-layer autophagosomes, in the presence of nutrient stress, injury, and fasting [1,2]. Along with cellular energy stability, autophagy contributes to the control of cellular quality, and destruction of abnormal proteins and damaged organelles [3]. As a result, the origin and development of many diseases, such as neurodegenerative disorders, cancer, and autoimmune diseases, can be explained by defective autophagy [4]. Data from multiple studies demonstrate a connection between type of diet and cancer medication [5]. It has been established that sufficient consumption of dietary and medicinal plant-derived biochemical compounds lowers the frequency of cancer mortality. This occurs due to the activation or balancing of various cellular oncogenes. In different human disorders, including cancer, there is documented evidence of reduction of autophagic regulation. Several lines of evidence have shown that cancer plays a critical role in inhibiting or augmenting autophagic pathways [6]. In addition, this dual role of autophagy has a significant therapeutic benefit against cancer [7]. The present report has established that natural product-derived bioactive molecules, along with lysosomal inhibitors, including chloroquine (CQ) and hydroxychloroquine (HCQ) are important regulators of autophagy signaling [8]. In addition, these proactive molecules can regulate the process of autophagy both *in vitro* and *in vivo* by involving the enzymes, transcription factors, and various intracellular communication pathways [9]. The autophagy stimulation or prohibition process is vastly complicated and regulated, so it needs to be extensively explored. However, emerging evidence has implicated that extreme or dysregulated autophagy might lead to a unique type of cell death known as autophagic cell death [10]. Conversely, the proposal of using natural compounds as anti-cancer and autophagy-modulating agents requires a better understanding of their cellular and molecular mechanisms. The mechanism of action needs to be further addressed.

In this review, we compiled the cellular and molecular mechanisms involved in the dual role of autophagy, as a tumor-suppressing as well as a tumor-augmenting phenomenon in cancer. Current improvements in the use of natural bioactive compounds for cancer treatment by targeting autophagic action have been consistently analyzed [11]. Given the vital role of autophagy in cancer prevention and treatment, we closely reviewed different plant-derived biomolecules that may play

a role in modulating the autophagy-linked signaling pathways as well as contribute towards competent treatment strategies against specific molecular aspects in cancer. In particular, administration of naturally derived compounds have been considered to regulate autophagy modulation, which might help improve our understanding of the mechanisms of natural compounds in the management and treatment of autophagy-linked diseases and cancers.

2. Mechanisms of autophagy signaling pathway

Autophagy is a sensitive and tightly mannered process that has multiple steps [12]. Proteins crucial for autophagy were first reported in yeast and are termed as autophagy-related (Atg) proteins [1,13]. Multiple sequential molecular events take place to initiate the autophagy signaling cascade. First, an Atg1/unc51-like kinase (ULK) complex kinase regulates the induction, and the BECN1/class III PI3K complex initiates the nucleation of vesicles [14]. In addition, ubiquitin-like conjugation systems (Atg12 and Atg8/LC3B) control vesicle elongation as well as retrieval of lipids mediated by transmembrane Atg9 and associated proteins, which involve other Atg proteins [15]. Lysosome-associated membrane protein 2 (LAMP2) and RAS-related protein-7 (RAB7A) participate in the fusion between lysosomes and autophagosome formation [16]. Finally, vesicle breakdown and degradation by lysosomal hydrolases produce recyclable products [17] (Figure 1). Microtubule-associated protein 1 light chain 3-beta (MAP1LC3B) and Atg5-Atg12 complex pathways, that are ubiquitin-like pathways, are regulatory for vesicle elongation and are encoded by the yeast Atg8 pathway, which has a human homologue [18]. Following the autophagy response, human Atg4 cysteine protease cleaves LC3B protein and thereby produces the LC3B-I isoform [19]. Activated LC3B-I isoform causes the activation of Atg7 protein through LC3B-I and is transported to the Atg3 before formation of the LC3B-II isoform by the phosphatidylethanolamine (PE) conjugation with the carboxyl glycine of LC3B-I protein [20]. As a consequence, elevated synthesis and processing of LC3B shows promising nature and has been mentioned as a key marker of autophagy [20]. In the degradation of matured autophagosomes through the enzymatic action of lysosomal enzymes, small molecules are produced that are used for de novo protein synthesis, helping in survival and maintenance of homeostasis [21].

Figure 1: Molecular mechanism of autophagy signaling. Autophagy is generally initiated by a deficiency of growth factors or nutrients that trigger AMPK or mTOR inhibition. This stimulates FIP200 and Atg13 associated ULK complex. After that phosphorylation of Beclin-1, it leads to the activation of VPS34 that further initiates the formation of phagophore. Conjugation of Atg5-Atg12 encompasses Atg7 as well as Atg10 to form an Atg12-Atg5-Atg16 complex which also stimulates the phagophores formation. Atg5 in addition to Atg12 makes an Atg16 complex which acts as an E3-function concerning LC3-PE assembly (LC3-II). This complex, likewise initiates the formation of a phagophore. Particularly, LC3-II is an autophagy marker that is ultimately interrupted via autolysosomes. Maturation of autophagosome leads to fusion with lysosomes in association with several lysosomal proteins, finally leading to degradation of cargo in addition to recycling of metabolites and nutrients.

3. Molecular mechanism of autophagy signaling in cancer pathogenesis

Under healthy conditions, cells have an innate ability for autophagy mechanisms to defend against malignant transformation [22]. Generally, autophagy is initiated by the induction of tumor-suppressing proteins, and oncoproteins are reported to inhibit this action [23]. Therefore, autophagy can act in both pro-survival and pro-death stages of tumor initiation and development [23]. The disturbed autophagy pathway can contribute to tumor development, as it leads to accumulation of damaged organelles and protein aggregates, which ultimately produce reactive oxygen species (ROS) and lead to genome instability [24]. Several researchers have reported that chemotherapeutics and avenues for cancer treatment can be accelerated by altering autophagic signaling that result in tumor cell death by inhibition of pro-survival and tissue specific apoptosis inducing factors [25]. Additionally, autophagy has been described to have a dual function in the promotion as well as inhibition of metastasis [26]. In the early stages, autophagy prevents metastasis, whereas in later stages it favors metastatic activity [26]. However, poorly vascularized tumor cells may survive at low nutrient and low oxygen levels through TGF- β , and other signals that trigger autophagy [27]. Furthermore, autophagy has directly regulated the metastatic cascade mainly through migration, invasion, and epithelial to mesenchymal transition (EMT) of cancer cells [26,28]. The importance of autophagy at diverse stages of tumorigenesis and metastasis is illustrated in Figure 2. It has been found that many cells within the tumors such as immune cells, fibroblasts, and endothelial cells are surrounded by the tumor microenvironment and have been acknowledged as an attractive target to reduce resistance to anticancer treatment. Natural compounds from vegetables, spices, marine organisms, herbs, and fruits have been reported to prevent or reverse multistage carcinogenesis as well as to prevent cancerous cell proliferation [29]. Additionally, microRNAs (miRNAs), that control the expression of genes, play an important role in diverse biological processes. It has been found that miRNA expression dysregulation is highly related to cancer development [30]. Recently, several studies have shown that natural compounds, such as paclitaxel (PTX), genistein, curcumin, epigallocatechin-3-gallate (EGCG), and resveratrol exhibit pro-apoptotic or anti-proliferative properties that are controlled by miRNAs, and lead to inhibition of cancer cell growth and proliferation, apoptosis induction, and improvement of conventional cancer treatment and therapeutic efficiency [30]. However, these naturally occurring compounds could be modulated by different signal transduction pathways through their connection

via cancer cells, tumor microenvironment, and miRNA. These have been described later in this study.

Figure 2: In cancer cells autophagy exhibits a dual role in metastasis and invasion. Depending on the stage and type of tumor cell, autophagy can prevent or stimulate cancer cell maintenance. In the early stages of autophagy in primary tumors, metastasis has been suppressed via anti-metastatic elements in addition to stimulation of tumor conservation along with progression by inducing cellular resistance against TRAIL, a tumor necrosis factor-related apoptosis-inducing ligand, to induce apoptosis. Later, in the course of invasion, tumor cells spread and enter lymphatic or blood vessels. Here, autophagy shows a pro-metastatic function through cell protection from anoikis triggered via extracellular matrix detachment.

3.1 Autophagy signaling roles in cancer inhibition

Several studies have reported that autophagy inhibition via manipulated pharmacological or genetic tools can be a possible chemotherapeutic option. Recently, scientists have focused on the

combined treatment of chemically synthesized autophagy inhibitors and traditional chemotherapeutics [31]. Cancer cell sensitization with 3-methyladenine (3-MA), wortmannin, CQ, LY294002, bafilomycin A1 (Baf A1), and HCQ - like inhibitors of autophagy to chemotherapeutic drugs have been reported to accelerate cell death pathway action [32,33]. In the abovementioned inhibitors, some of them are preliminary stage inhibitors of autophagy like wortmannin, LY294002, and 3-MA, that block the autophagosomes formation while others act on the basis of lysosomal action at late stages [34]. Table 1 shows several valuable effects of natural compounds combined with some autophagy inhibitors in different cellular cancer models. In breast cancer cells, the pro-survival nature of cancer cells can be downregulated by LC3 via shRNA blocking and sensitization of the carcinoma cells to apoptotic factors such as trastuzumab [35]. In leukemia, pro-survival function with pharmacological inhibitors or RNA interference (RNAi) can also block accelerated induced cell death by imatinib mesylate [36]. Autophagy can sensitize and make cells susceptible to radiotherapy, such as HBL-100 cells, for radiotherapy treatment, and 3-MA leads to the inhibition of autophagy by imposing the pro-death effects of therapy [37]. In BIF-1 knockout mice, there is impairment of autophagy in addition to increase in the rate of tumor formation, while mutations in UVRAG decrease autophagy along with increased proliferation of colorectal cancer cells [38]. These reports propose that Beclin-1 acts as an insufficient tumor-suppressor gene and fully incorporates the theory of tumor-suppressive autophagy induction at early stages [39]. In the livers of mice, Atg gene deletion can lead to the formation of multiple benign tumors. In systematic mosaic Atg5 and Atg7 deletion mice, these specific deletions magnify the chance of tumor induction and lead to tumor development [40]. At early stages of cancer formation, Atg4 suppresses tumor developing activity and Atg4c deficiency is proven to be more easily identifiable in chemical carcinogen-induced fibrosarcoma. These reports help to understand the suppressive roles of autophagy in cancer with genetic deletion of specific regions [41].

Table 1: Mechanism of action of combination of natural compounds and autophagy blockers, 3-methyladenine (3-MA), chloroquine (CQ), and bafilomycin A1 (Baf A1) in modulating autophagy and apoptosis in various cancer cell models

Natural compound/ Chemical	Cell model	Molecular mechanisms	Combination with autophagy inhibitors	References
18 α -Glycyrrhetic acid	Neuroblastoma	Autophagy and apoptosis induction	CQ combination induces cell death	[42]
Resveratrol	Glioblastomas	Induction of apoptosis and autophagy via reduces ROS/MAPK pathway	Baf A1 combination augments apoptotic cell death	[43]
Curcumin	Glioblastomas	Induction of Autophagy and apoptosis	CQ combination rises apoptotic cell death	[44]
Gintonin	Cortical astrocytes and Glioblastoma cells	Induction of autophagy	CQ and Baf A1 combination stimulates autophagy	[45]
Quercetin	U373MG cells	PI3K/Akt inhibition and causes apoptosis and autophagy	CQ combination increases apoptotic cell death	[46]
Paclitaxel	Human lung carcinoma A549 cells	Induction of Autophagy and apoptosis	3-MA combination enhances apoptotic cell death	[47]
Genistein	MIA PaCa-2 human pancreatic cancer cell	Autophagy and apoptosis induction	CQ combination stimulates apoptotic cell death	[48]
Honokiol	Non-small cell lung cancer A549 and H460 cells	p62 and LC3 induces autophagy induction	Combination of CQ triggered apoptosis	[49]
Ginsenoside compound K	Neuroblastoma SK-N-BE(2) and SH-SY5Y cells	ROS-mediated autophagy inhibition and apoptosis induction	Combination of CQ inhibit autophagy and induces apoptosis	[50]
Oxyresveratrol	Neuroblastoma SK-N-BE(2) and SH-SY5Y cells	PI3K/AKT/mTOR pathway independent autophagy and apoptosis	3-MA combination enhances apoptotic cell death	[51]

3.2 Autophagy signaling roles in cancer promotion

Autophagy induction is a possible anti-cancer mechanism in which cancer cells have a faulty or altered apoptotic cell death pathway [52]. Consequently, autophagy induction along with autophagy inhibition can induce apoptosis and exert anti-cancer effects [53]. Several inhibitors, such as Bcl-2, EGFR, and mTOR, are currently used in cancer treatment [54]. Inhibitory molecules

are known to be effective against a variety of cancers, and some induce autophagy in breast cancers, gliomas, and lung cancers through rapamycin, an inhibitor of mTORC2 [54]. Another known inhibitor of the mTOR, deforolimus (AP23573, MK-8669), is proposed to treat patients with relapsed or refractory hematologic malignancies [55]. Another antibody against epidermal growth factor, cetuximab, can regulate autophagic cell death in cancer cells by disrupting the interaction between Bcl-2 and Beclin-1 [56]. Several reports explain that the expression of the viral oncogenes Kirsten and Harvey RAS virus is capable of autophagy induction in certain cells [57]. In pancreatic and colorectal cancer cells, elevated levels of RAS mutations are reported to be correlated with higher autophagy rates, where increased levels maintain cell proliferation in RAS-activated tumors and inhibition of autophagy results in reduced cell proliferation, ultimately leading to tumor regression [58]. Lung cancers are also dependent on autophagy, which is similar to the mechanism of RAS-driven cancers regulated by valine-to-glutamic acid substitution at BRAF position 600 (BRAV600E) [59]. *In vivo* studies have reported that deletion of subunit FIP200 related to the ULK1 complex in autophagy initiation blocks the growth of breast cancer and extends the life cycle of mice [60]. In addition, activated AMPK generated by ATP can also trigger an autophagic event [61].

4. Natural compounds triggers in autophagy modulation

A single therapeutic strategy or a combination modality can both be favorable for cancer treatment. The various strategies include radiation therapy, immune or genetic therapy, and chemotherapy, all of which are creating new diversions and avenues in the field of cancer treatment with adequate levels of safety and accuracy [15,62,63]. Natural compounds are effective in the positive regulation of anticancer activity, as they inhibit cellular proliferation, adjust the oxidative stress response, and manipulate autophagic signaling and response [15,64]. This entire response of natural compounds is dependent on the cell type. The role of several natural compounds that modulate different pathways of autophagy signaling is illustrated in Figure 3.

Figure 3: Key autophagy pathway and its regulators (natural compounds) to treat diverse cancers. This figure is modified from Wang et al. [65]. Natural compounds activate autophagy by several autophagic signaling targets and show a close relationship with cancer development and control. Multiple signaling pathways are activated or inhibited by natural compounds to modulate cancer cells.

4.1 Inhibition of autophagy by natural compounds for cancer therapy

Apigenin: Apigenin, a flavonoid found in vegetables and fruits, can initiate tumor cell death through autophagy and apoptosis [66]. In combination with retinamide N-(4-hydroxyphenyl) and apigenin suppresses autophagy and increases apoptosis in human neuroblastoma (NB) cells [67].

Genistein: Genistein, a nutritive natural compound, has been documented to repress autophagy and induce apoptosis of human colon cancer HT-29 cells alone with downregulation of the PI3K/Akt signaling pathway [68]. Another mechanism of action of genistein is that it also exerts an antiproliferative effect on ovarian cancer cells through autophagy as well as apoptosis [68]. Genistein augmented miR-451 expression and improved isoproterenol-mediated cardiac hypertrophy [69]. Furthermore, genistein increased miR-1469 expression and prevented Mcl-1 expression in laryngeal cancer [70].

Indole-3-carbinol: Indole-3-carbinol, a natural compound collected from cruciferous vegetables, usually inhibits the PI3K/Akt pathway along with blockage of autophagy signaling in human colon cancer HT-29 cells [68].

Plumbagin: Plumbagin, is obtained from *Plumbago zeylandica* L root and has a prompt antiproliferative activity through autophagic cell death, mediated via inhibition of AKT/mTOR pathway in human cervical cancer cells [71].

4.2 Induction of autophagy by natural compounds as potential cancer therapy

Antroquinonol: Antroquinonol, produced from *Antrodia Camphorata*, shows anti-tumor activity in various cancer cells [72]. Non-small cell lung cancer (NSCLC) as well as human pancreatic cancer, PANC-1 and ASPC-1, have been demonstrated to exhibit inhibitory effects of antroquinonol via the PI3K/Akt/mTOR pathway [73]. The anti-proliferative effect of antroquinonol is related to apoptosis, autophagic cell death, and rapid senescence of the pancreatic cells [73]. Several studies have demonstrated that antroquinonol can be introduced for the treatment of neoplasms [74]. A proposed clinical trial in metastatic pancreatic carcinoma is aimed at evaluating the anticancer activity of antroquinonol in combination with nab-PTX and gemcitabine [75].

18 α -Glycyrrhetic acid: 18 α -Glycyrrhetic acid (18-GA), a known gap-junction inhibitor, has been shown to demonstrate anticancer properties in human NB cells [42]. 18-GA has been shown to induce autophagy as well as apoptosis. Autophagy increases Atg5, Atg7, and LC3II along with degradation of p62 (Figure 4). Furthermore, 18-GA, along with the autophagy inhibitor CQ, exhibits significant cell death in NB cells. Moreover, the Bcl-2/Beclin-1 interaction in addition to the cleavage of Beclin-1 has been revealed by 18-GA in autophagy and apoptosis induced cell death. Eventually, caspase-3 siRNA and pan-caspase inhibitor treatment have been inhibited to prevent 18-GA-induced cellular cytotoxicity, indicating that caspase-mediated apoptosis induction has been observed in human NB cells [42].

Figure 4: 18 α -Glycyrrhetic acid-mediated cell death in human neuroblastoma cells. 18-GA induces mitochondria-mediated apoptosis to alter mitochondrial membrane potential in a significant change in with Bax/Bcl-2 ratio. Autophagy related proteins Atg5/7, Beclin-1, LC3, and p62 were activated during 18-GA-mediated autophagic cell death. Beclin-1 contributes to autophagy in addition to apoptosis induction in 18-GA-mediated cell death. Additionally, ROS and ER stress showed no changes during 18-GA treatment in SH-SY5Y and B103.

270 **Celastrol:** Celastrol, a popular natural medicinal compound triperine secreted from *Tripterygium*
271 *wilfordii* Hook, is a polyubiquitinated aggregate that degrades the autophagy substrate p62 in the
272 human glioblastoma (GBM) cancer cells [76]. Celastrol-mediated cytotoxicity was not sensitized
273 by adjustment with autophagy inhibitors. Paraptosis-like cytoplasmic vacuolization can be induced
274 by celastrol and has been associated with autophagy and the initiation of apoptosis in PC-3, A549,
275 and HeLa cancer cells [77]. Celastrol can be used to treat fever, joint pain, and edema without
276 causing any side effects [78]. Recently, many research studies have identified celastrol as a
277 neuroprotective agent via a collaborative drug screen that can be used for the treatment of many
278 neurodegenerative diseases.

279 **Monanchocidin A:** An active novel alkaloid, monanchocidin A, has been recently isolated from
280 *Monanchora pulchra*, a marine sponge [79]. Monanchocidin can initiate autophagy and lysosomal
281 membrane permeabilization in tumor cells [79]. Many studies have demonstrated that
282 monanchocidin A can inhibit human urogenital cancers, including germ cell tumors, through
283 autophagy signaling [80].

284 **Paclitaxel:** PTX, a natural medicinal compound isolated from *Taxus brevifolia* Nutt, shows a vast
285 range of effect against various types of cancer such as breast, endometrial, bladder, and cervical
286 cancer, by influencing the autophagy pathway [81]. The US Food and Drug Administration (FDA)
287 has approved PTX for the treatment of ovarian cancer and early stage breast cancer. The anticancer
288 activity of PTX is increased when PTX is combined with cisplatin or carboplatin, and the combined
289 compound can be used for the early treatment of advanced ovarian cancer [82]. It has been shown
290 that PTX can inhibit the initial stage of autophagy, along with apoptosis, under normoxic and
291 hypoxic conditions in human breast cancer cells [83]. PTX-initiated apoptosis was combined with
292 the initiation of autophagy in A549 lung cancer cells [84]. Treatment with PTX also initiated acidic
293 vesicular organelle formation, Beclin-1, Atg5, and LC3 expression, and the prevention of
294 autophagy proceeds via PTX-mediated cell death [85,86]. Autophagy can promote PTX-mediated
295 cell death. In human breast cancer cells, PTX prevents autophagy via an individual mechanism
296 based on the cell-cycle phase [86].

297 **Gintonin:** Gintonin (GT), a novel ginseng-derived exogenous ligand of lysophosphatidic acid
298 (LPA) receptors, has shown to induce autophagy in cortical astrocytes [87]. GT intensely

augmented the autophagy marker LC3 via the G protein-coupled LPA receptor-mediated pathway. However, GT-mediated autophagy was considerably decreased via autophagy inhibition 3-MA as well as Beclin-1, Atg5, and Atg7 gene knockdown [15,87]. Notably, pretreatment with a lysosomotropic agent, Baf A1 and E-64d/peps A, GT significantly improved LC3-II levels in addition to the formation of LC3 puncta (Figure 5). Furthermore, GT treatment improved autophagic flux, which influenced lysosome-associated membrane protein 1 (LAMP1) in addition to degradation of the autophagy substrate ubiquitinated p62/SQSTM1 protein in mouse cortical astrocytes [87].

Figure 5: Gintonin (GT) activates autophagy in mouse cortical astrocytes. GT-mediated autophagy was dependent on GPCR-LPA receptors. Pretreatment with an LPA receptor antagonist, Ki16425, considerably decreased GT-mediated autophagy, while LPA agonist pretreatment, LPA 18:1, augmented autophagy in astrocytes. Autophagy initiation proteins Atg5, Atg7, and Beclin-1 were found to be activated in GT-mediated autophagy in astrocytes. Inhibition of autophagy by 3-MA, GT-mediated autophagy was prevented. Pretreated with E-64d/pepstatin A and bafilomycin

314 A1, GT additionally improved LC3 puncta formation indicating enhanced autophagic flux in
315 cortical astrocytes. GT treatment increased acidic vacuole formation along with p62 protein
316 accumulation during this autophagy process.

317 **β -elemene:** β -elemene, derived from *Rhizoma Curcumae*, is a natural terpenoid bioactive
318 compound that shows strong activity against various types of cancers [40]. In the human body, β -
319 elemene works against the PI3K/Akt/mTOR/p70S6K pathway that induces autophagy and
320 apoptosis of human NSCLCA549 cells [88]. As β -elemene increases the antitumor effect,
321 autophagy is prevented by the interception with chloroquine [88]. In human renal-cell carcinoma
322 786-0 cells, β -elemene is used for the inhibition of the MAPK/ERK and P13K/Akt/mTOR
323 signaling pathways to initiate defensive autophagy and apoptosis [89].

324 **Caffeine:** In HeLa cells, the Akt/mTOR/p70S6K pathway initiates autophagy and apoptotic cell
325 death under the influence of caffeine that is routinely consumed in beverages [90].

326 **Curcumin:** Curcumin is a non-toxic toxic polyphenol with yellow pigment isolated from the
327 rhizome of *Curcuma longa* L [91]. Curcumin-associated autophagy is considered to be a signal for
328 cellular death in various types of cancer cells in the human body. Nevertheless, in the human body,
329 curcumin can induce cellular differentiation and cellular survival by regulating the activities of
330 AKT-AMPK-mediated autophagy induction [92]. Thus, it prevents the growth of malignant
331 glioma cells *in vitro* and *in vivo*. Curcumin is used to induce non-apoptotic autophagy cell death
332 in U87-MG and U373-MG malignant glioma cells [93]. This activity is related to the G2/M phase
333 cell cycle attack, the prevention of the ribosomal S6 protein kinase pathway with the ERK1/ERK2
334 activation pathway [93]. Curcumin is responsible for Atg apoptosis in mesothelioma and k562
335 long-standing myelogenous leukemia cells by AKT/mTOR and NF- κ B signaling pathways [94].
336 Curcumin can be used as an effective therapeutic compound in cancer management and is well
337 endured, as confirmed by preclinical data in clinical experiments [91]. Curcumin has been found
338 to suppress TGF- β expression, such as p-SMAD2, TGF- β 3, MMP-13, and NF- κ B tumor-
339 promoting factors as well as metastatic active adhesion molecules, such as intercellular adhesion
340 molecule 1 (ICAM-1) and β 1-integrin in stromal fibroblasts and colorectal cancer cells [95]. In
341 addition, MiR-1246 has been shown to be involved in curcumin-induced radiosensitizing actions
342 on bladder cancer cells by targeting p53 translation [96].

Tetrahydrocurcumin: Tetrahydrocurcumin (THC), is one of the strongest bioactive natural metabolite derived from curcumin. THC effectively shows strong antioxidant, anticancer, and cardioprotective properties [97]. The action of THC on autophagy was assessed by the decrease in the PI3K/Akt-mTOR and MAPK signaling pathways and initiation of caspase-7 mediated apoptosis [98].

Oxyresveratrol: Oxyresveratrol (Oxy R), 4-[(E)-2-(3,5-dihydroxyphenyl) ethenyl] benzene-1,3-diol/ 2,3,4,5-tetrahydroxy-trans-stilbene found in *Morus alba*, has been shown to activate autophagy and apoptotic cell death in NB cells [51] (Figure 6). Oxy R-mediated autophagic cells were independent of apoptotic cell death. The PI3K/AKT/mTOR and p38 MAPK pathways control Oxy R-induced cell death in SH-SY5Y human NB cells [51].

Figure 6: Natural compound oxyresveratrol (Oxy R) stimulates apoptosis and autophagy dependent cell death. Oxy R activates autophagy through autophagy initiation Atg7 and Beclin 1 dependent pathway. Atg7 knockdown prevents autophagy, but activates apoptotic cell death in

SH-SY5Y cells. Blockage of autophagy via 3-MA, Oxy R inhibits autophagic cell death. When apoptosis signaling is inhibited by Z-DEVD-FMK caspase-3 inhibitor, Oxy R exhibits autophagic cell death.

Epigallocatechin-3-gallate: The activity of cisplatin and oxaliplatin-initiated autophagy was promoted by EGCG in HT-29 and DLD-1 colorectal cancer cells, as identified by the multiplication of LC3B-II protein and autophagosome organization [99]. EGCG initiated autophagy as well as apoptosis in SSC-4 squamous cell carcinoma in combination with the upregulation of FAS, BAK, BAD, IGF-IR, WNT11, and ZEB1 proteins along with downregulation of MYC, TP53, and CASP8 proteins [100]. The formation of autophagosomes is increased by EGCG. In hepatic cells, the processes of lysosomal acidification and autophagic flux are also increased by EGCG *in vitro* as well as *in vivo* [101]. Remarkably, luteolin and EGCG combination repressed TGF- β -mediated demonstration of myofibroblast phenotypes by reducing RhoA as well as ERK activation [102]. EGCG suggestively repressed rat hepatic stellate cells proliferation through hindering expression of PDGF- β receptor and tyrosine phosphorylation [103]. Furthermore, it has been found that EGCG attenuates uric acid-mediated NRK-49 F cell injury by up-regulating miR-9, and successively by JAK-STAT as well as NF- κ B signaling pathway activation [104]. EGCG reduces carcinoma cell growth probably by regulating miRNA expression, and may be a potential beneficial target for the prevention of cancers.

Fisetin: Fisetin (3, 7, 3', 4'-tetrahydroxyflavone), a flavonol and a member of flavonoid polyphenols [105], is usually isolated from many vegetables and fruits [105]. Fisetin can function as an inhibitor of the expression of PI3K/Akt/mTOR pathways and regulate autophagy in prostate cancer and human NSCLC cells [106,107]. Fisetin has been found to inhibit the mTOR pathway and induce autophagy in human prostate cancer cells [108]. In addition, the effects of fisetin on autophagy are cell-type specific because fisetin inhibits autophagy in MCF-7 breast cancer cells and induces caspase-7-mediated apoptosis [109].

γ -Tocotrienol: Tocotrienols and the isoforms of vitamin E are differentiated on the basis of their antioxidant, anti-inflammatory, and anticancer properties. γ -tocotrienol induces endoplasmic inflammation and autophagy-associated cell death [110]. Pretreatment with the autophagy inhibitors 3-MA or Baf1 prevented the γ -tocotrienol-initiated cytotoxicity [111]. Many other

studies have demonstrated that in mouse mammary cancer cells, the attachment of γ -tocotrienol with oridonin effectively initiated both autophagic and apoptotic effects [112]. The potency of autophagy cellular markers was significantly enhanced by the attachment of γ -tocotrienol with oridonin [113]. Simultaneously, this potency also improved the transformation of LC3-I to LC3-II, Atg3, Atg7, Beclin-1, Atg5-Atg12, LAMP-1, and cathepsin-D.

Geraniol: Fruits, vegetables, and cereal grains contain geraniol, a secondary metabolite, that in human PC-3 prostate cancer cells, was shown to induce apoptosis and Atg cell death [114].

Seriniquinone: Seriniquinone is a medicinal compound derived from a marine bacterium of the genus *Serinicoccus*. It exhibits effective anti-proliferative activity against melanoma cell lines by activation of autophagocytosis [115].

Thymoquinone: Thymoquinone (TQ) is a key bioactive natural product isolated from black cumin, *Nigella sativa* L. TQ is related to increased volumes of autophagic vacuoles as well as LC3 proteins and enhances the combination of autophagosomes in the head and neck squamous carcinoma cells [116]. TQ effectively reduced the growth rate of GBM cells in association with the lysosomal inhibitor CQ, mostly causing apoptosis, and initiating autophagy [117]. LC3-II and p62 proteins are enhanced by the expression of TQ [117]. It was also shown that TQ prevented the growth of irinotecan-inhibited LoVo colon cancer cells by primarily activating apoptosis before autophagy [118]. Activation of the p38 and JNK MAP kinase pathways is related to TQ, which causes autophagic cell death [118]. TQ-induced caspase and autophagic cell death were also related to mitochondrial outward membrane penetrability [117].

Magnolol: Magnolol, isolated from *Magnolia officinalis*, exhibited anti-cancer and anti-tumor activity by directing autophagy and apoptosis signaling pathways [119]. However, magnolol promotes autophagy-mediated cell death in human non-small lung cancer H460 cells at high concentrations [120]. Additionally, in SGC-7901 human gastric adenocarcinoma cells, magnolol has been shown to repress PI3K/Akt pathway and encourage death by inducing autophagy [121].

Polyphenol mulberry extract: Mulberry is derived from *Morus Alba* leaf, which modulates the autophagy AMPK/PI3K/Akt pathway [122]. In Hep3B human hepatocellular carcinoma cells, mulberry extract modulates autophagic or apoptotic cell death by the activation of the p53-

414 dependent pathway [123]. It has been found that in NB cells, *Morus alba* root extract initiates
415 apoptosis through FOXO-Caspase-3 dependent pathway [124].

416 **Oblongifolin C:** Oblongifolin C (OC), isolated from *Garcinia yunnanensis* Hu, is a strong
417 autophagy inhibitor [125]. Treatment with OC resulted in an augmented number of
418 autophagosomes as well as reduced SQSTM1/p62 and degradation [126]. OC showed anticancer
419 effectiveness by improved staining of LC3 puncta, SQSTM1, and cleaved CASP-3, along with
420 decreased expression levels of lysosomal cathepsins *in an in vivo* xenograft mouse model [125].

421 **Naphthazarin:** Naphthazarin repressed the Akt/PI3K pathway by activating autophagy and
422 apoptosis pathways and by inducing A549 lung cancer cell death [127].

423 **Sulforaphane:** Sulforaphane is derived from cruciferous vegetables, such as cauliflower, cabbage,
424 broccoli, and hoary weed [128]. In human prostate cancer PC-3 cells, sulforaphane has been shown
425 to prompt autophagosome formation as well as acidic vesicular organelle formation [129].
426 Sulforaphane augmented the protein levels of LC3B-I in addition to encouraging LC3B-II
427 processing. Exposure to sulforaphane in tumor cells displayed LC3B-II puncta related to
428 autophagosome formation [130]. It also disrupted BECN1/BCL-2 interaction, causing autophagy
429 initiation through the release of BECN1. Phosphorylated AKT-Ser473 levels were decreased by
430 sulforaphane in addition to simultaneous treatment with autophagy inhibitors, 3-MA or CQ, and
431 inhibited tumor cell growth and proliferation [131]. Sulforaphane initiation decreases oxidative
432 stress in addition to misfolded protein accumulation [132].

433 **Mollugin:** A bioactive phytochemical, mollugin, sequestered from *Rubia cordifolia* L., showed
434 anticancer potential against numerous cancer cells [133]. Additional studies confirmed that the
435 mTOR and ERK pathways are involved in mollugin-prompted autophagy in addition to apoptosis
436 [134].

437 **Jujuboside B:** Jujuboside B is a saponin found in the seeds of *Zizyphus jujubavar* Spinose. It
438 increased autophagy and apoptosis in human HCT-116 and AGS gastric adenocarcinoma cells *in*
439 *vitro* and successfully repressed tumor growth in a xenograft model of nude mice *in vivo* [135].
440 Furthermore, jujuboside B activated p38/JNK-mediated autophagy induction through cytoplasmic
441 vacuole formation in addition to LC3-I/II conversion [135].

442 **Cyclovirobuxine D:** Cyclovirobuxine D (CVB-D) has been shown to activate autophagy in the
443 human MCF-7 breast cancer cell line through the addition of autophagosomes as well as raised
444 LC3 puncta, along with augmented conversion of LC3-I to LC3-II [136]. However, CVB-D-
445 mediated autophagy induction and cell viability have been blocked by 3-MA [136].

446 **Polygonatum odoratum lectin:** Polygonatum odoratum lectin (POL) was shown to reveal
447 apoptosis-inducing and anti-proliferative properties in a wide range of cancer cells [137]. In human
448 breast cancer NSCLC A549 and MCF-7 cells, POL could prompt both autophagy and apoptosis
449 [138]. POL stimulated apoptosis by preventing the AKT/NF- κ B pathway, whereas augmented
450 autophagy through AKT-mTOR pathway suppression [138].

451 **Resveratrol:** Resveratrol, a polyphenol compound derived from berries, red grapes, and peanuts,
452 has been shown to facilitate cell death in a diverse variety of cancer cells through autophagy,
453 apoptosis, and necrosis [139,140]. In ovarian cancer cells, resveratrol has been found to activate
454 autophagic cell death [141]. However, resveratrol inhibited NF- κ B stimulation in association with
455 augmented permeability of lysosomal in cervical cancer cells, demonstrating autophagic cell death
456 [142]. Additionally, in HL-60 promyelocytic leukemia cells, it has been described that resveratrol-
457 prompted apoptosis increased LC3-II levels in addition to dependency on mTOR pathway [143].
458 Meanwhile, resveratrol-mediated apoptosis was related to reduced p53 and AMPK/mTOR
459 autophagy signaling pathways in renal carcinoma cells [144]. The antiproliferative action of
460 resveratrol has been found in liver myofibroblasts by preventing PDGF signaling and decreasing
461 EGF-dependent DNA synthesis [145]. Additionally, in retinal endothelial cells, resveratrol has
462 been found to increase miR15a expression under conditions of high glucose levels and decreased
463 insulin signaling [146].

464 **Quercetin:** Quercetin, a bioflavonoid, is generally found in fruits, beverages, and vegetables. *In*
465 *vitro* and *in vivo* studies have shown that it exhibits antiproliferative activities in numerous tumors
466 conventionally related to its antioxidant properties [147].

467 **Rottlerin:** Rottlerin, a natural product sequestered from *Mallotus philippinensis*, repressed
468 PI3K/mTOR signaling in human pancreatic cancer stem cells, and activated autophagy-mediated
469 apoptotic cell death [148].

470 **Angelicin:** Angelicin, a psoralen, is derived from *Angelica polymorpha* and has been shown to
471 induce apoptosis [149,150] and autophagy [151]. Angelicin increased autophagy related proteins
472 Atg3, Atg7 and Atg12-5 with phosphorylation of mTOR [151,152].

473 **Ursolic acid:** A triterpenoid phytochemical, ursolic acid (UA), has been found to activate
474 autophagy by inducing LC3 in addition to p62 protein accumulation [153]. In HCT15 cells, UA
475 repressed growth by modulating autophagy in the JNK pathway [154]. However, UA induced
476 cytotoxicity in addition to repressing concentration-dependent TC-1 cervical cancer cells by
477 controlling Atg5 and LC3-II, which demonstrated its anticancer activity [153]. Furthermore, in
478 MCF7 breast cancer cells, UA activated autophagy under ER stress [155]. In PC3 prostate cancer
479 cells, UA-induced autophagy has been facilitated by the Akt/mTOR and Beclin-1 pathways [156].

480 **Polygonatum Cyrtonema Lectin:** Polygonatum Cyrtonema Lectin (PCL) inhibits the PI3K-Akt
481 pathway in addition to prompting autophagy and apoptosis in cancer cells [157]. Although PCL
482 significantly prevented the growth of A375 human melanoma cells, normal melanocytes have not
483 been affected [158]. Additionally, PCL has been found to stimulate both autophagy and apoptosis
484 in A375 cells [159].

485 **Silibinin:** Silibinin, derived from *Silybum marianum*, has been shown to induce autophagic
486 HT1080 cell death in human fibrosarcoma through diverse mechanisms, including inhibition of
487 MEK/ERK and PI3K/Akt pathways [160].

488 **Plant extract induces autophagy:** Several plant-derived extracts from *Dioscorea nipponica*
489 Makino, *Melandrium firmum*, marine algae, and natural flavonoids have been found to induce
490 apoptosis and autophagic properties [161-164]. *Saussurea lappa* ethanol extract has been
491 investigated to activate apoptosis in NB [165] and autophagy in LNCaP prostate cancer cells [166].

492 **Ginsenoside Rk1:** Ginsenoside Rk1, an NMDA receptor inhibitor [167], exhibited antitumor and
493 autophagy modulation activities in HepG2 cells. Rk1-prompted autophagy was recognized
494 through LC3-I to LC3-II conversion, which incorporated lysosomes into the autolysosome process
495 [168]. However, the autophagy inhibitor, Beclin 1 siRNA or bafilomycin A1, and Rk1 combination
496 boosted autophagic activities in HepG2 [168].

Climacostol: In mouse B16-F10 melanoma cells, autophagosomes accumulate with dysfunctional autophagic degradation. However, climacostol provides mechanistic insights and promotes autophagosome turnover through the p53-AMPK pathway and activated p53 protein levels [169].

5. Role of natural compounds in autophagy modulation of neurodegenerative diseases

Natural plant-derived compounds are able to modulate autophagy and can be used to develop treatments for neurodegenerative diseases such as Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), Amyotrophic lateral sclerosis (ALS), Spinocerebellar ataxia (SCA), and NB [170]. Oleuropein aglycone (OLE), a natural phenol, can protect the A β -driven cytotoxicity of neuronal cells by stimulating autophagy found in *in vitro* and *in vivo* examinations, thereby easing A β toxicity clearance of AD. [171,172]. Arctigenin, derived from *Arctium lappa* (L.), inhibits A β production by decreasing BACE1 and boosts A β clearance by increasing autophagy via AKT/mTOR inhibition [173]. Another polyphenol, resveratrol, significantly repressed A β aggregation via autophagy, and showed antioxidant effects in AD [174-176]. Kaempferol, a flavone, increases autophagy and encourages mitochondrial damage repair, protecting neuronal cells against death via rotenone-induced toxicity in PD models [177]. *U. rhynchophylla* contains alkaloids of oxindole and was found to prompt Beclin-1-dependent as well as mTOR-independent autophagy, which stimulates α -synuclein clearance in *the Drosophila* model of A53T wide-type and mutant [178]. Conophylline, *Tavertaemontana divaricate*-derived vinca alkaloid, has been shown to promote α -synuclein degradation via the mTOR-independent pathway in MPP⁺-mediated neurotoxin [179]. Curcumin, a polyphenol from *Curcuma longa* turmeric plant, has been shown to exhibit neuroprotective properties against PD models via mTOR-dependent autophagy and preventing oxidative stress, inflammation, and α -synuclein aggregation. [180]. Trehalose, resveratrol, and onjisaponin B improve autophagic degradation α -synuclein when treated with MPTP-induced mice in addition to stimulating AMPK and sirtuin 1 protein [181,182]. A natural alkaloid, harmine, has been found to stimulate α -synuclein removal by PKA-mediated PD pathogenesis of UPS activation [183]. Distinct AD, PD, and HD neurodegenerative syndrome might be treated via natural compounds through modulation of autophagy [1]. *Nelumbo nucifera* contains neferine which has been shown to protect Htt mutant proteins via autophagy triggering with the AMPK/mTOR pathway [184]. Aggregate-prone mutant Htt protein has been removed by trehalose through an mTOR-independent autophagy pathway

[185]. Berberine, an isoquinoline alkaloid, has been shown to prevent mutant Htt protein accumulation and activate autophagy in mouse and cell models of HD [186]. In particular, trehalose has been found to stimulate mTOR-independent autophagy in superoxide dismutase mutant mice in the management of ALS *in vivo* [187]. Trehalose and its analogs, such as lactulose and melibiose, have been designated to substantially reduce the aggregation of abnormal ataxin-3 by stimulation of autophagy, which reduces free radical production [188], indicating that natural compounds might be used as a therapeutic approach to control SCA.

6. Effect of natural compounds on solid tumors and lymphomas

Neuroblastoma, the most common extracranial solid malignant tumor of childhood, is the third most common form of pediatric malignancy worldwide. Didymnin, a dietary flavonoid glycoside, has been found to be effective in NB treatment [189]. A *Morus alba* root extract compound, Oxy R, has been shown to accumulate ROS as well as induce autophagic and apoptotic cell death in NB cells via the FOXO and caspase-3 induction pathway [51,124]. A psoralen compound angelicin derived from *Angelica polymorpha*, increases cytotoxicity in addition to inducing apoptosis through anti-apoptotic proteins (Bcl-xL, Bcl-2, and Mcl-1) downregulation in SH-SY5Y human NB cells [149,150]. However, *Saussurea lappa* Clarke, *Dioscorea nipponica* Makino, and *Melandrium firmum* extracts have been shown to have apoptotic and anti-proliferative effects in NB cells [161,165,190]. Additionally, curcumin, propolis, quercetin, icariin, withaferin A, tetrandrine, and resveratrol has been used for the treatment of aggressive GBM [191]. In addition, a combination therapy with temozolomide and resveratrol substantially diminished the growth of GBM cells in a xenograft model [192]. Natural compounds such as PTX, wortmannin, and beta-lapachone have been found to be involved in the ARF/MDM2-MDMX/p53 signaling pathway in the human retinoblastoma (RB) Y79 cell line [193].

Lymphoma is the most common type of blood cancer, and various natural compounds have been used to treat lymphomas. Several natural compounds have shown anticancer effects on lymphomas (Table 2). *Nigella sativa* Linn. contain TQ has been shown to induce apoptosis and ROS production at 5 and 10 mM concentrations of 24 h treatment in ABC-DLBCL, activated B cell lymphoma cell lines [194]. It has been stated that fuxocanthinol induces apoptosis in addition to arrest in cell cycle progression in lymphoma cells [195].

556 Table 2: Anticancer effects of natural cancers in the management of lymphomas

Natural compounds	Cellular/animal models	Concentrations/doses	Effects and mechanisms	References
Thymoquinone from <i>Nigella sativa</i>	Activated B cell lymphoma cell lines	5-10 mM	ROS production and apoptosis	[194]
Resveratrol	Neuroblastoma	30 μ M	Apoptosis induction and antiproliferative	[140]
Fuxocanthinol	Primary effusion lymphomas BCBL-1 and TY-1	1.3-5 μ M	Apoptosis induction and cell cycle arrest	[195]
Curcumin	CH12F3 lymphoma cells	5 μ M	Caspase-3 dependent apoptosis and DNA damage	[196]
Peperobtusin A	Lymphoma U937 cells	25, 50, 100 μ M	Caspase-3, 8, 9 dependent apoptosis and p38 MAPK	[197]
11(13)-dehydroivaxillin (DHI)	Lymphoid malignancies of NHL cells xenografts	5, 7, 10 μ M	Induction of NF- κ B and apoptosis	[198]
Psilostachyin C	Murine lymphoma cell line BW5147	0.01–50 μ g/ml	Induction of apoptosis, necrosis, and ROS generation	[199]

557
558 Curcumin has been reported to induce antitumor effects on CH12F3 cell lines through DNA breaks
559 and apoptosis [196]. Extracts from *Peperomia tetraphylla*, Peperobtusin A, has been found to
560 induce S phase cell cycle arrest and p38 MAPK dependent apoptosis in U937 cells [197]. However,
561 induction of apoptosis, necrosis, and cell cycle arrest by psilostachyin C has been found in
562 lymphoma BW5147 cell lines [199]. In a xenograft mouse model, 11(13)-dehydroivaxillin (DHI)
563 has shown antitumor activity via the apoptosis pathway [198].

564 7. Therapeutic view of autophagy in heart/cardiovascular diseases

565 Autophagy has shown to play a major regulatory role in cellular longevity [200] and in
566 heart/cardiovascular diseases towards maintaining homeostasis by conserving cardiac function and
567 structure [201] and to determine a potential connection between ventricular fibrillation and

autophagy [202]. Evidences have described that mitochondrial autophagy downregulation plays a vital role in mitochondrial dysfunction as well as heart failure, while re-establishment of mitochondrial autophagy mitigates this heart dysfunction [203]. It has been revealed that cardiac myocytes are reduced through autophagy inhibitor, 3-MA, with AMP-activated protein kinase (AMPK) activation via inactivation of mTOR under glucose deprivation [204]. In addition, the autophagy related gene, Beclin-1, defends the heart in LPS-induced sepsis in a mouse model and targets autophagy induction, and therefore has an important role with therapeutic potential for treating cardiovascular diseases [205]. At high glucose conditions, it has been found that hemoxygenase-1 (HO-1) overexpression via human HO-1 recombinant plasmid inhibited dysfunction of cardiac arrest, improved autophagy levels. Numerous hemin concentrations induce HO-1, which affects endothelial cell mitochondrial dysfunction. Likewise, exposure to hemin further prompts mitophagy, although it is not adequate to inhibit cell death [206]. It has been found that regulating Sirt3 concentration in myocytes via proper autophagy expression in diverse stages of myocardial ischemia-reperfusion might decrease the morbidity of patients with myocardial infarction accurately in the future [207]. Metformin has been used to treat cardiotoxicity induced by doxorubicin via the autophagy pathway [208]. In contrast, a non-selective β -adrenergic agonist, isoproterenol, has been investigated for the treatment of autophagy as well as cell death pathway induced cardiac injury such as necrosis or apoptosis induced cardiac injury [209]. Currently, it has been accepted that pharmacological approaches to target autophagy and apoptosis have been useful in the treatment of coronary heart disease, therefore providing a new favorable therapeutic intervention in the future [210]. Hence, consideration of emerging molecular mechanisms towards the understanding of autophagy has recently gained importance to regulate cellular systems that can be used to prevent and treat cardiovascular disease [211].

8. Perspectives of naturally occurring autophagy modulators in cancer therapy

Despite anti-cancer drug development, natural compounds contribute to cancer and cancer stem cell [212] suppressive action without any severe complications, and thus it is an emerging topic with respect to autophagy. Natural compounds have also appeared as unique therapeutic agents for cancer and drug repositioning via their impact on autophagy [213]. It is remarkable that the study of cell fate by natural stimulators should be the focal point, although the technological dissimilarities of autophagy detection may affect the outcome. In addition, *in vivo* examination of

natural stimulators of autophagy in cancer therapy or prevention will be an emerging field of research in the future. Moreover, studies on the effects of natural product-derived molecules on autophagy should be highlighted at the translational level.

9. Conclusions and future directions

Cancer cells can convert and reuse necessary amino acids by imposing autophagic signaling pathways, thereby ensuring their consistent growth and longevity. Accordingly, autophagy serves a dual role in cancer; augmentation or hindrance can either boost or down-regulate cancer cell proliferation. As a result, autophagy moderators can play the role of a promising novel therapeutic approach towards cancer inhibition by helping overcome resistance against chemotherapy and radiotherapy. Potential targets of autophagic progress and autophagosome formation in the initial phase and lysosomal deterioration in the late phase have been considered. However, mTOR and AMPK are the leading regulatory molecules of autophagy in upstream signaling pathways. These are also known targets for natural compound derived modulators of autophagy. Therefore, using plant-derived and semisynthetic components to target the regulation of the entire pathway can provide an opportunity to design a powerful remedy for cancer patients.

614 **Acknowledgements**

615 This work was supported by NRF Research Program (2016M3C7A1913845) and the Korea
616 Research Fellowship (KRF) Program (M.A.R. 2016H1D3A1908615; R.I.
617 2020H1D3A1A04104782) funded by the Ministry of Science and ICT, Republic of Korea, and
618 also supported by the RP-Grant 2020 of Ewha Womans University, Republic of Korea.

619

620 **Authors' Contributions**

621 Conceptualization M.A.R. Writing and original draft preparation by M.S.H, P.B, R.I, M.H.R.
622 Figures are drawing by M.H.R. Review and editing, M.J.U. Visualization and supervision H.R.
623 All authors have read and agreed to the published version of the manuscript.

624

625 **Conflicts of Interest:** The authors declare no conflict of interest.

References

- [1] M.A. Rahman, H. Rhim, Therapeutic implication of autophagy in neurodegenerative diseases, *BMB Rep* 50 (2017) 345-354. 10.5483/bmbrep.2017.50.7.069.
- [2] O. Corti, K. Blomgren, A. Poletti, P.M. Beart, Autophagy in neurodegeneration: New insights underpinning therapy for neurological diseases, *J Neurochem* (2020) e15002. 10.1111/jnc.15002.
- [3] M.S. Uddin, A. Stachowiak, A. Al Mamun, N.T. Tzvetkov, S. Takeda, A.G. Atanasov, L.B. Bergantin, M.M. Abdel-Daim, A.M. Stankiewicz, Autophagy and Alzheimer's Disease: From Molecular Mechanisms to Therapeutic Implications, *Front Aging Neurosci* 10 (2018). ARTN 4 10.3389/fnagi.2018.00004.
- [4] D.S. Arroyo, E.A. Gaviglio, J.M.P. Ramos, C. Bussi, M.C. Rodriguez-Galan, P. Iribarren, Autophagy in inflammation, infection, neurodegeneration and cancer, *Int Immunopharmacol* 18 (2014) 55-65. 10.1016/j.intimp.2013.11.001.
- [5] R.J. Perry, G.I. Shulman, Mechanistic Links between Obesity, Insulin, and Cancer, *Trends Cancer* 6 (2020) 75-78. 10.1016/j.trecan.2019.12.003.
- [6] Y. Ling, R. Perez-Soler, Disruption of autophagic and autolysosomal signaling pathways leads to synergistic augmentation of erlotinib-induced apoptosis in wild type EGFR human non-small cell lung cancer cell lines, *Ejc Suppl* 8 (2010) 183-183. Doi 10.1016/S1359-6349(10)72289-8.
- [7] C.G. Towers, D. Wodetzki, A. Thorburn, Autophagy and cancer: Modulation of cell death pathways and cancer cell adaptations, *J Cell Biol* 219 (2020). 10.1083/jcb.201909033.
- [8] G. Manic, F. Obrist, G. Kroemer, I. Vitale, L. Galluzzi, Chloroquine and hydroxychloroquine for cancer therapy, *Mol Cell Oncol* 1 (2014) e29911. 10.4161/mco.29911.
- [9] R. Khandia, M. Dadar, A. Munjal, K. Dhama, K. Karthik, R. Tiwari, M.I. Yattoo, H.M.N. Iqbal, K.P. Singh, S.K. Joshi, W. Chaicumpa, A Comprehensive Review of Autophagy and Its Various Roles in Infectious, Non-Infectious, and Lifestyle Diseases: Current Knowledge and Prospects for Disease Prevention, Novel Drug Design, and Therapy, *Cells-Basel* 8 (2019). ARTN 674 10.3390/cells8070674.
- [10] S. Bialik, S.K. Dasari, A. Kimchi, Autophagy-dependent cell death - where, how and why a cell eats itself to death, *J Cell Sci* 131 (2018). ARTN jcs215152 10.1242/jcs.215152.
- [11] R. Lagoa, J. Silva, J.R. Rodrigues, A. Bishayee, Advances in phytochemical delivery systems for improved anticancer activity, *Biotechnol Adv* 38 (2020). ARTN 107382 10.1016/j.biotechadv.2019.04.004.
- [12] S. Tavakol, M. Ashrafizadeh, S. Deng, M. Azarian, A. Abdoli, M. Motavaf, D. Poormoghdam, H. Khanbabaei, E.G. Afshar, A. Mandegary, A. Pardakhty, C.T. Yap, R. Mohammadinejad, A.P. Kumar, Autophagy Modulators: Mechanistic Aspects and Drug Delivery Systems, *Biomolecules* 9 (2019). ARTN 530 10.3390/biom9100530.
- [13] E. Hirata, Y. Ohya, K. Suzuki, Atg4 plays an important role in efficient expansion of autophagic isolation membranes by cleaving lipidated Atg8 in *Saccharomyces cerevisiae*, *Plos One* 12 (2017). ARTN e0181047 10.1371/journal.pone.0181047.
- [14] Y. Chen, J. He, M. Tian, S.Y. Zhang, M.R. Guo, R. Kasimu, J.H. Wang, L. Ouyang, UNC51-like kinase 1, autophagic regulator and cancer therapeutic target, *Cell Proliferat* 47 (2014) 494-505. 10.1111/cpr.12145.

668 [15] M.A. Rahman, M.R. Rahman, T. Zaman, M.S. Uddin, R. Islam, M.M. Abdel-Daim, H. Rhim, Emerging
 669 Potential of Naturally Occurring Autophagy Modulators Against Neurodegeneration, *Curr Pharm Design*
 670 26 (2020) 772-779. 10.2174/1381612826666200107142541.
 671 [16] S. Nakamura, T. Yoshimori, New insights into autophagosome-lysosome fusion, *J Cell Sci* 130 (2017)
 672 1209-1216. 10.1242/jcs.196352.
 673 [17] H. Schulze, T. Kolter, K. Sandhoff, Principles of lysosomal membrane degradation Cellular topology
 674 and biochemistry of lysosomal lipid degradation, *Bba-Mol Cell Res* 1793 (2009) 674-683.
 675 10.1016/j.bbamcr.2008.09.020.
 676 [18] T. Shpilka, H. Weidberg, S. Pietrokovski, Z. Elazar, Atg8: an autophagy-related ubiquitin-like protein
 677 family, *Genome Biol* 12 (2011). ARTN 226
 678 10.1186/gb-2011-12-7-226.
 679 [19] A. Agrotis, L. von Chamier, H. Oliver, K. Kiso, T. Singh, R. Ketteler, Human ATG4 autophagy proteases
 680 counteract attachment of ubiquitin-like LC3/GABARAP proteins to other cellular proteins, *J Biol Chem* 294
 681 (2019) 12610-12621. 10.1074/jbc.AC119.009977.
 682 [20] A.H. Lystad, A. Simonsen, Mechanisms and Pathophysiological Roles of the ATG8 Conjugation
 683 Machinery, *Cells-Basel* 8 (2019). ARTN 973
 684 10.3390/cells8090973.
 685 [21] C. Ward, N. Martinez-Lopez, E.G. Otten, B. Carroll, D. Maetzel, R. Singh, S. Sarkar, V.I. Korolchuk,
 686 Autophagy, lipophagy and lysosomal lipid storage disorders, *Bba-Mol Cell Biol L* 1861 (2016) 269-284.
 687 10.1016/j.bbailp.2016.01.006.
 688 [22] L. Galluzzi, F. Pietrocola, J.M. Bravo-San Pedro, R.K. Amaravadi, E.H. Baehrecke, F. Cecconi, P.
 689 Codogno, J. Debnath, D.A. Gewirtz, V. Karantza, A. Kimmelman, S. Kumar, B. Levine, M.C. Maiuri, S.J.
 690 Martin, J. Penninger, M. Piacentini, D.C. Rubinsztein, H.U. Simon, A. Simonsen, A.M. Thorburn, G. Velasco,
 691 K.M. Ryan, G. Kroemer, Autophagy in malignant transformation and cancer progression, *Embo J* 34 (2015)
 692 856-880. 10.15252/embj.201490784.
 693 [23] V. Desantis, I. Saltarella, A. Lamanuzzi, M.A. Mariggio, V. Racanelli, A. Vacca, M.A. Frassanito,
 694 Autophagy: A New Mechanism of Prosurvival and Drug Resistance in Multiple Myeloma, *Transl Oncol* 11
 695 (2018) 1350-1357. 10.1016/j.tranon.2018.08.014.
 696 [24] Z.N.J. Yang, C.E. Chee, S.B. Huang, F.A. Sinicrope, The Role of Autophagy in Cancer: Therapeutic
 697 Implications, *Mol Cancer Ther* 10 (2011) 1533-1541. 10.1158/1535-7163.Mct-11-0047.
 698 [25] M.S. Ricci, W.X. Zong, Chemotherapeutic approaches for targeting cell death pathways, *Oncologist*
 699 11 (2006) 342-357. DOI 10.1634/theoncologist.11-4-342.
 700 [26] E.E. Mowers, M.N. Sharifi, K.F. Macleod, Autophagy in cancer metastasis, *Oncogene* 36 (2017) 1619-
 701 1630. 10.1038/onc.2016.333.
 702 [27] B.J. Altman, J.C. Rathmell, Metabolic Stress in Autophagy and Cell Death Pathways, *Csh Perspect Biol*
 703 4 (2012). ARTN a008763
 704 10.1101/cshperspect.a008763.
 705 [28] E.E. Mowers, M.N. Sharifi, K.F. Macleod, Functions of autophagy in the tumor microenvironment and
 706 cancer metastasis, *Febs J* 285 (2018) 1751-1766. 10.1111/febs.14388.
 707 [29] S.A. Park, Y.J. Surh, Modulation of tumor microenvironment by chemopreventive natural products,
 708 *Ann N Y Acad Sci* 1401 (2017) 65-74. 10.1111/nyas.13395.
 709 [30] B. Zhang, L. Tian, J. Xie, G. Chen, F. Wang, Targeting miRNAs by natural products: A new way for cancer
 710 therapy, *Biomed Pharmacother* 130 (2020) 110546. 10.1016/j.biopha.2020.110546.
 711 [31] J.W. Jiang, L. Zhang, H.N. Chen, Y.L. Lei, T. Zhang, Y.L. Wang, P. Jin, J. Lan, L. Zhou, Z. Huang, B.W. Li,
 712 Y. Liu, W. Gao, K. Xie, L.X. Zhou, E.C. Nice, Y. Peng, Y.H. Cao, Y.Q. Wei, K. Wang, C.H. Huang, Regorafenib

induces lethal autophagy arrest by stabilizing PSAT1 in glioblastoma, *Autophagy* 16 (2020) 106-122. 10.1080/15548627.2019.1598752.

[32] F. Cuomo, L. Altucci, G. Cobellis, Autophagy Function and Dysfunction: Potential Drugs as Anti-Cancer Therapy, *Cancers* 11 (2019). ARTN 1465 10.3390/cancers11101465.

[33] K.M. Livesey, D.L. Tang, H.J. Zeh, M.T. Lotze, Autophagy inhibition in combination cancer treatment, *Curr Opin Invest Dr* 10 (2009) 1269-1279.

[34] Y.T. Wu, H.L. Tan, G.H. Shui, C. Bauvy, Q. Huang, M.R. Wenk, C.N. Ong, P. Codogno, H.M. Shen, Dual Role of 3-Methyladenine in Modulation of Autophagy via Different Temporal Patterns of Inhibition on Class I and III Phosphoinositide 3-Kinase, *J Biol Chem* 285 (2010) 10850-10861. 10.1074/jbc.M109.080796.

[35] A. Vazquez-Martin, C. Oliveras-Ferraro, J.A. Menendez, Autophagy Facilitates the Development of Breast Cancer Resistance to the Anti-HER2 Monoclonal Antibody Trastuzumab, *Plos One* 4 (2009). ARTN e6251 10.1371/journal.pone.0006251.

[36] K. Rothe, V. Porter, X.Y. Jiang, Current Outlook on Autophagy in Human Leukemia: Foe in Cancer Stem Cells and Drug Resistance, Friend in New Therapeutic Interventions, *Int J Mol Sci* 20 (2019). ARTN 461 10.3390/ijms20030461.

[37] G.H. Jo, O. Bogler, Y.J. Chwae, H. Yoo, S.H. Lee, J.B. Park, Y.J. Kim, J.H. Kim, H.S. Gwak, Radiation-Induced Autophagy Contributes to Cell Death and Induces Apoptosis Partly in Malignant Glioma Cells, *Cancer Res Treat* 47 (2015) 221-241. 10.4143/crt.2013.159.

[38] S.S. He, Z. Zhao, Y.F. Yang, D. O'Connell, X.W. Zhang, S. Oh, B.Y. Ma, J.H. Lee, T. Zhang, B. Varghese, J. Yip, S.D. Pirooz, M. Li, Y. Zhang, G.M. Li, S.E. Martin, K. Machida, C.Y. Liang, Truncating mutation in the autophagy gene UVRAG confers oncogenic properties and chemosensitivity in colorectal cancers, *Nat Commun* 6 (2015). ARTN 7839 10.1038/ncomms8839.

[39] Z.Y. Yue, S.K. Jin, C.W. Yang, A.J. Levine, N. Heintz, Beclin 1, an autophagy gene essential for early embryonic development, is a haploinsufficient tumor suppressor, *P Natl Acad Sci USA* 100 (2003) 15077-15082. 10.1073/pnas.2436255100.

[40] A. Takamura, M. Komatsu, T. Hara, A. Sakamoto, C. Kishi, S. Waguri, Y. Eishi, O. Hino, K. Tanaka, N. Mizushima, Autophagy-deficient mice develop multiple liver tumors, *Gene Dev* 25 (2011) 795-800. 10.1101/gad.2016211.

[41] X. Yang, D.D. Yu, F. Yan, Y.Y. Jing, Z.P. Han, K. Sun, L. Liang, J. Hou, L.X. Wei, The role of autophagy induced by tumor microenvironment in different cells and stages of cancer, *Cell Biosci* 5 (2015). ARTN 14 10.1186/s13578-015-0005-2.

[42] M.A. Rahman, K. Bishayee, K. Habib, A. Sadra, S.O. Huh, 18alpha-Glycyrrhetic acid lethality for neuroblastoma cells via de-regulating the Beclin-1/Bcl-2 complex and inducing apoptosis, *Biochem Pharmacol* 117 (2016) 97-112. 10.1016/j.bcp.2016.08.006.

[43] C.J. Lin, C.C. Lee, Y.L. Shih, T.Y. Lin, S.H. Wang, Y.F. Lin, C.M. Shih, Resveratrol enhances the therapeutic effect of temozolomide against malignant glioma in vitro and in vivo by inhibiting autophagy, *Free Radic Biol Med* 52 (2012) 377-391. 10.1016/j.freeradbiomed.2011.10.487.

[44] A. Zanutto-Filho, E. Braganhol, K. Klafke, F. Figueiro, S.R. Terra, F.J. Paludo, M. Morrone, I.J. Bristot, A.M. Battastini, C.M. Forcelini, A.J.R. Bishop, D.P. Gelain, J.C.F. Moreira, Autophagy inhibition improves the efficacy of curcumin/temozolomide combination therapy in glioblastomas, *Cancer Lett* 358 (2015) 220-231. 10.1016/j.canlet.2014.12.044.

757 [45] M.A. Rahman, H. Hwang, S.Y. Nah, H. Rhim, Gintonin stimulates autophagic flux in primary cortical
758 astrocytes, *Journal of Ginseng Research* 44 (2020) 67-78. 10.1016/j.jgr.2018.08.004.

759 [46] H. Kim, J.Y. Moon, K.S. Ahn, S.K. Cho, Quercetin induces mitochondrial mediated apoptosis and
760 protective autophagy in human glioblastoma U373MG cells, *Oxid Med Cell Longev* 2013 (2013) 596496.
761 10.1155/2013/596496.

762 [47] G. Xi, X. Hu, B. Wu, H. Jiang, C.Y. Young, Y. Pang, H. Yuan, Autophagy inhibition promotes paclitaxel-
763 induced apoptosis in cancer cells, *Cancer Lett* 307 (2011) 141-148. 10.1016/j.canlet.2011.03.026.

764 [48] R. Suzuki, Y. Kang, X. Li, D. Roife, R. Zhang, J.B. Fleming, Genistein potentiates the antitumor effect of
765 5-Fluorouracil by inducing apoptosis and autophagy in human pancreatic cancer cells, *Anticancer Res* 34
766 (2014) 4685-4692.

767 [49] X.Q. Lv, F. Liu, Y. Shang, S.Z. Chen, Honokiol exhibits enhanced antitumor effects with chloroquine by
768 inducing cell death and inhibiting autophagy in human non-small cell lung cancer cells, *Oncol Rep* 34 (2015)
769 1289-1300. 10.3892/or.2015.4091.

770 [50] J.M. Oh, E. Kim, S. Chun, Ginsenoside Compound K Induces Ros-Mediated Apoptosis and Autophagic
771 Inhibition in Human Neuroblastoma Cells In Vitro and In Vivo, *Int J Mol Sci* 20 (2019).
772 10.3390/ijms20174279.

773 [51] M.A. Rahman, K. Bishayee, A. Sadra, S.O. Huh, Oxyresveratrol activates parallel apoptotic and
774 autophagic cell death pathways in neuroblastoma cells, *Biochim Biophys Acta Gen Subj* 1861 (2017) 23-
775 36. 10.1016/j.bbagen.2016.10.025.

776 [52] M. Russo, G.L. Russo, Autophagy inducers in cancer, *Biochem. Pharmacol.* 153 (2018) 51-61.
777 10.1016/j.bcp.2018.02.007.

778 [53] S.I. Nunez-Olvera, D. Gallardo-Rincon, J. Puente-Rivera, Y.M. Salinas-Vera, L.A. Marchat, R. Morales-
779 Villegas, C. Lopez-Camarillo, Autophagy Machinery as a Promising Therapeutic Target in Endometrial
780 Cancer, *Front Oncol* 9 (2019). ARTN 1326
781 10.3389/fonc.2019.01326.

782 [54] Y.Y. Wu, H.C. Wu, J.E. Wu, K.Y. Huang, S.C. Yang, S.X. Chen, C.J. Tsao, K.F. Hsu, Y.L. Chen, T.M. Hong,
783 The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status,
784 as a potent accompanist in combined therapeutic regimens, *J Exp Clin Canc Res* 38 (2019). ARTN 282
785 10.1186/s13046-019-1282-0.

786 [55] D.A. Rizzieri, E. Feldman, J.F. DiPersio, N. Gabrail, W. Stock, R. Strair, V.M. Rivera, M. Albitar, C.L.
787 Bedrosian, F.J. Giles, A phase 2 clinical trial of deforolimus (AP23573, MK-8669), a novel mammalian target
788 of rapamycin inhibitor, in patients with relapsed or refractory hematologic malignancies, *Clin Cancer Res*
789 14 (2008) 2756-2762. 10.1158/1078-0432.Ccr-07-1372.

790 [56] X. Li, Y. Lu, T. Pan, Z. Fan, Roles of autophagy in cetuximab-mediated cancer therapy against EGFR,
791 *Autophagy* 6 (2010) 1066-1077. 10.4161/auto.6.8.13366.

792 [57] L. Galluzzi, F. Pietrocola, J.M. Bravo-San Pedro, R.K. Amaravadi, E.H. Baehrecke, F. Cecconi, P.
793 Codogno, J. Debnath, D.A. Gewirtz, V. Karantza, A. Kimmelman, S. Kumar, B. Levine, M.C. Maiuri, S.J.
794 Martin, J. Penninger, M. Piacentini, D.C. Rubinsztein, H.U. Simon, A. Simonsen, A.M. Thorburn, G. Velasco,
795 K.M. Ryan, G. Kroemer, Autophagy in malignant transformation and cancer progression, *Embo J* 34 (2015)
796 856-880. 10.15252/embj.201490784.

797 [58] A. Lauzier, J. Normandeau-Guimond, V. Vaillancourt-Lavigueur, V. Boivin, M. Charbonneau, N. Rivard,
798 M.S. Scott, C.M. Dubois, S. Jean, Colorectal cancer cells respond differentially to autophagy inhibition in
799 vivo, *Sci Rep* 9 (2019) 11316. 10.1038/s41598-019-47659-7.

800 [59] A.M. Strohecker, E. White, Autophagy promotes BrafV600E-driven lung tumorigenesis by preserving
801 mitochondrial metabolism, *Autophagy* 10 (2014) 384-385. 10.4161/auto.27320.

802 [60] Y. Avalos, J. Canales, R. Bravo-Sagua, A. Criollo, S. Lavandero, A.F. Quest, Tumor suppression and
803 promotion by autophagy, *Biomed Res Int* 2014 (2014) 603980. 10.1155/2014/603980.

804 [61] A. Shteingauz, Y. Porat, T. Voloshin, R.S. Schneiderman, M. Munster, E. Zeevi, N. Kaynan, K. Gotlib, M.
805 Giladi, E.D. Kirson, U. Weinberg, A. Kinzel, Y. Palti, AMPK-dependent autophagy upregulation serves as a
806 survival mechanism in response to Tumor Treating Fields (TTFields), *Cell Death Dis* 9 (2018). ARTN 1074
807 10.1038/s41419-018-1085-9.

808 [62] M.A. Rahman, M.S. Rahman, M.J. Uddin, A.N.M. Mamum-Or-Rashid, M.G. Pang, H. Rhim, Emerging
809 risk of environmental factors: insight mechanisms of Alzheimer's diseases, *Environ Sci Pollut R* (2020).
810 10.1007/s11356-020-08243-z.

811 [63] H.H.W. Chen, M.T. Kuo, Improving radiotherapy in cancer treatment: Promises and challenges,
812 *Oncotarget* 8 (2017) 62742-62758. 10.18632/oncotarget.18409.

813 [64] H. Luo, C.T. Vong, H.B. Chen, Y. Gao, P. Lyu, L. Qiu, M.M. Zhao, Q. Liu, Z.H. Cheng, J. Zou, P.F. Yao, C.F.
814 Gao, J.C. Wei, C.O.L. Ung, S.P. Wang, Z.F. Zhong, Y.T. Wang, Naturally occurring anti-cancer compounds:
815 shining from Chinese herbal medicine, *Chin Med-Uk* 14 (2019). ARTN 48
816 10.1186/s13020-019-0270-9.

817 [65] P.Q. Wang, L.J. Zhu, D.J. Sun, F.H. Gan, S.Y. Gao, Y.Y. Yin, L.X. Chen, Natural products as modulator of
818 autophagy with potential clinical prospects, *Apoptosis* 22 (2017) 325-356. 10.1007/s10495-016-1335-1.

819 [66] E.J. Choi, G.H. Kim, Apigenin Induces Apoptosis through a Mitochondria/Caspase-Pathway in Human
820 Breast Cancer MDA-MB-453 Cells, *J Clin Biochem Nutr* 44 (2009) 260-265. DOI 10.3164/jcbrn.08-230.

821 [67] N. Mohan, N.L. Banik, S.K. Ray, Combination of N-(4-hydroxyphenyl) retinamide and apigenin
822 suppressed starvation-induced autophagy and promoted apoptosis in malignant neuroblastoma cells,
823 *Neurosci Lett* 502 (2011) 24-29. 10.1016/j.neulet.2011.07.016.

824 [68] Y. Nakamura, S. Yogosawa, Y. Izutani, H. Watanabe, E. Otsuji, T. Sakai, A combination of indol-3-
825 carbinol and genistein synergistically induces apoptosis in human colon cancer HT-29 cells by inhibiting
826 Akt phosphorylation and progression of autophagy, *Mol Cancer* 8 (2009) 100. 10.1186/1476-4598-8-100.

827 [69] M.L. Gan, T. Zheng, L.Y. Shen, Y. Tan, Y. Fan, S.R. Shuai, L. Bai, X.W. Li, J.Y. Wang, S.H. Zhang, L. Zhu,
828 Genistein reverses isoproterenol-induced cardiac hypertrophy by regulating miR-451/TIMP2, *Biomedicine*
829 *& Pharmacotherapy* 112 (2019). ARTN 108618
830 10.1016/j.biopha.2019.108618.

831 [70] C.H. Ma, Y.X. Zhang, L.H. Tang, X.J. Yang, W.M. Cui, C.C. Han, W.Y. Ji, MicroRNA-1469, a p53-
832 responsive microRNA promotes Genistein induced apoptosis by targeting Mcl1 in human laryngeal cancer
833 cells, *Biomedicine & Pharmacotherapy* 106 (2018) 665-671. 10.1016/j.biopha.2018.07.005.

834 [71] P.L. Kuo, Y.L. Hsu, C.Y. Cho, Plumbagin induces G2-M arrest and autophagy by inhibiting the
835 AKT/mammalian target of rapamycin pathway in breast cancer cells, *Mol Cancer Ther* 5 (2006) 3209-3221.
836 10.1158/1535-7163.MCT-06-0478.

837 [72] V. Thiyagarajan, M.J. Tsai, C.F. Weng, Antroquinonol Targets FAK-Signaling Pathway Suppressed Cell
838 Migration, Invasion, and Tumor Growth of C6 Glioma, *Plos One* 10 (2015) e0141285.
839 10.1371/journal.pone.0141285.

840 [73] C.C. Yu, P.C. Chiang, P.H. Lu, M.T. Kuo, W.C. Wen, P.N. Chen, J.H. Guh, Antroquinonol, a natural
841 ubiquinone derivative, induces a cross talk between apoptosis, autophagy and senescence in human
842 pancreatic carcinoma cells, *J Nutr Biochem* 23 (2012) 900-907. 10.1016/j.jnutbio.2011.04.015.

843 [74] P.C. Chiang, S.C. Lin, S.L. Pan, C.H. Kuo, I.L. Tsai, M.T. Kuo, W.C. Wen, P. Chen, J.H. Guh, Antroquinonol
844 displays anticancer potential against human hepatocellular carcinoma cells: A crucial role of AMPK and
845 mTOR pathways, *Biochem. Pharmacol.* 79 (2010) 162-171. 10.1016/j.bcp.2009.08.022.

[75] J.F. Chiou, A.T.H. Wu, W.T. Wang, T.H. Kuo, J.G. Gelovani, I.H. Lin, C.H. Wu, W.T. Chiu, W.P. Deng, A Preclinical Evaluation of Antrodia camphorata Alcohol Extracts in the Treatment of Non-Small Cell Lung Cancer Using Non-Invasive Molecular Imaging, *Evid-Based Compl Alt* (2011) 1-12. 10.1093/ecam/nep228.

[76] R. Kannaiyan, K.A. Manu, L.X. Chen, F. Li, P. Rajendran, A. Subramaniam, P. Lam, A.P. Kumar, G. Sethi, Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways, *Apoptosis* 16 (2011) 1028-1041. 10.1007/s10495-011-0629-6.

[77] W.B. Wang, L.X. Feng, Q.X. Yue, W.Y. Wu, S.H. Guan, B.H. Jiang, M. Yang, X. Liu, D.A. Guo, Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90, *J Cell Physiol* 227 (2012) 2196-2206. 10.1002/jcp.22956.

[78] H. Li, Y.Y. Zhang, H.W. Tan, Y.F. Jia, D. Li, Therapeutic effect of tripterine on adjuvant arthritis in rats, *J Ethnopharmacol* 118 (2008) 479-484. 10.1016/j.jep.2008.05.028.

[79] S.A. Dyshlovoy, J. Hauschild, K. Amann, K.M. Tabakmakher, S. Venz, R. Walther, A.G. Guzii, T.N. Makarieva, L.K. Shubina, S.N. Fedorov, V.A. Stonik, C. Bokemeyer, S. Balabanov, F. Honecker, G.V. Amsberg, Marine alkaloid Monanchocidin a overcomes drug resistance by induction of autophagy and lysosomal membrane permeabilization, *Oncotarget* 6 (2015) 17328-17341. DOI 10.18632/oncotarget.4175.

[80] S.A. Dyshlovoy, S. Venz, J. Hauschild, K.M. Tabakmakher, K. Otte, R. Madanchi, R. Walther, A.G. Guzii, T.N. Makarieva, L.K. Shubina, S.N. Fedorov, V.A. Stonik, C. Bokemeyer, S. Balabanov, F. Honecker, G.V. Amsberg, Anti-migratory activity of marine alkaloid monanchocidin A - proteomics-based discovery and confirmation, *Proteomics* 16 (2016) 1590-1603. 10.1002/pmic.201500334.

[81] W.P. McGuire, J.A. Blessing, D. Moore, S.S. Lentz, G. Photopulos, Paclitaxel has moderate activity in squamous cervix cancer: A gynecologic oncology group study, *J Clin Oncol* 14 (1996) 792-795. Doi 10.1200/Jco.1996.14.3.792.

[82] N.C. Kampan, M.T. Madondo, O.M. McNally, M. Quinn, M. Plebanski, Paclitaxel and Its Evolving Role in the Management of Ovarian Cancer, *Biomed Research International* (2015). Artn 413076 10.1155/2015/413076.

[83] Y. Qiu, P. Li, C.Y. Ji, Cell Death Conversion under Hypoxic Condition in Tumor Development and Therapy, *Int J Mol Sci* 16 (2015) 25536-25551. 10.3390/ijms161025536.

[84] G.M. Xi, X.Y. Hu, B.L. Wu, H.M. Jiang, C.Y.F. Young, Y.X. Pang, H.Q. Yuan, Autophagy inhibition promotes paclitaxel-induced apoptosis in cancer cells, *Cancer Letters* 307 (2011) 141-148. 10.1016/j.canlet.2011.03.026.

[85] Y. Lee, J. Na, M.S. Lee, E.Y. Cha, J.Y. Sul, J.B. Park, J.S. Lee, Combination of pristimerin and paclitaxel additively induces autophagy in human breast cancer cells via ERK1/2 regulation, *Mol Med Rep* 18 (2018) 4281-4288. 10.3892/mmr.2018.9488.

[86] R.A. Veldhoen, S.L. Banman, D.R. Hemmerling, R. Odsen, T. Simmen, A.J. Simmonds, D.A. Underhill, I.S. Goping, The chemotherapeutic agent paclitaxel inhibits autophagy through two distinct mechanisms that regulate apoptosis, *Oncogene* 32 (2013) 736-746. 10.1038/onc.2012.92.

[87] M.A. Rahman, H. Hwang, S.Y. Nah, H. Rhim, Gintonin stimulates autophagic flux in primary cortical astrocytes, *J Ginseng Res* 44 (2020) 67-78. 10.1016/j.jgr.2018.08.004.

[88] J. Liu, X.J. Hu, B. Jin, X.J. Qu, K.Z. Hou, Y.P. Liu, ss-Elemente induces apoptosis as well as protective autophagy in human non-small-cell lung cancer A549 cells, *J Pharm Pharmacol* 64 (2012) 146-153. 10.1111/j.2042-7158.2011.01371.x.

[89] Y.H. Zhan, J. Liu, X.J. Qu, K.Z. Hou, K.F. Wang, Y.P. Liu, B. Wu, beta-Elemente Induces Apoptosis in Human Renal-cell Carcinoma 786-0 Cells through Inhibition of MAPK/ERK and PI3K/Akt/mTOR Signalling Pathways, *Asian Pac J Cancer P* 13 (2012) 2739-2744. 10.7314/Apjcp.2012.13.6.2739.

891 [90] S. Saiki, Y. Sasazawa, Y. Imamichi, S. Kawajiri, T. Fujimaki, I. Tanida, H. Kobayashi, F. Sato, S. Sato, K.I.
892 Ishikawa, M. Imoto, N. Hattori, Caffeine induces apoptosis by enhancement of autophagy via
893 PI3K/Akt/mTOR/p70S6K inhibition, *Autophagy* 7 (2011) 176-187. 10.4161/auto.7.2.14074.

894 [91] M. Lopez-Lazaro, Anticancer and carcinogenic properties of curcumin: Considerations for its clinical
895 development as a cancer chemopreventive and chemotherapeutic agent, *Mol Nutr Food Res* 52 (2008)
896 S103-S127. 10.1002/mnfr.200700238.

897 [92] H. Aoki, Y. Takada, S. Kondo, R. Sawaya, B.B. Aggarwal, Y. Kondo, Evidence that curcumin suppresses
898 the growth of malignant gliomas in vitro and in vivo through induction of autophagy: Role of Akt and
899 extracellular signal-regulated kinase signaling pathways, *Mol Pharmacol* 72 (2007) 29-39.
900 10.1124/mol.106.033167.

901 [93] N.V. Klinger, S. Mittal, Therapeutic Potential of Curcumin for the Treatment of Brain Tumors,
902 *Oxidative Med. Cell. Longevity* (2016). ArtN 9324085
903 10.1155/2016/9324085.

904 [94] L. Masuelli, M. Benvenuto, E. Di Stefano, R. Mattera, M. Fantini, G. De Feudis, E. De Smaele, I. Tresoldi,
905 M.G. Giganti, A. Modesti, R. Bei, Curcumin blocks autophagy and activates apoptosis of malignant
906 mesothelioma cell lines and increases the survival of mice intraperitoneally transplanted with a malignant
907 mesothelioma cell line, *Oncotarget* 8 (2017) 34405-34422. 10.18632/oncotarget.14907.

908 [95] C. Buhrmann, P. Kraehe, C. Lueders, P. Shayan, A. Goel, M. Shakibaei, Curcumin Suppresses Crosstalk
909 between Colon Cancer Stem Cells and Stromal Fibroblasts in the Tumor Microenvironment: Potential Role
910 of EMT, *Plos One* 9 (2014). ARTN e107514
911 10.1371/journal.pone.0107514.

912 [96] R. Xu, H.B. Li, S.Q. Wu, J. Qu, H.Y. Yuan, Y.G. Zhou, Q. Lu, MicroRNA-1246 regulates the radio-
913 sensitizing effect of curcumin in bladder cancer cells via activating P53, *Int Urol Nephrol* 51 (2019) 1771-
914 1779. 10.1007/s11255-019-02210-5.

915 [97] B.B. Aggarwal, L. Deb, S. Prasad, Curcumin Differs from Tetrahydrocurcumin for Molecular Targets,
916 Signaling Pathways and Cellular Responses, *Molecules* 20 (2015) 185-205. 10.3390/molecules20010185.

917 [98] J.C. Wu, C.S. Lai, V. Badmaev, K. Nagabhushanam, C.T. Ho, M.H. Pan, Tetrahydrocurcumin, a major
918 metabolite of curcumin, induced autophagic cell death through coordinative modulation of PI3K/Akt-
919 mTOR and MAPK signaling pathways in human leukemia HL-60 cells, *Mol Nutr Food Res* 55 (2011) 1646-
920 1654. 10.1002/mnfr.201100454.

921 [99] F. Hu, F. Wei, Y.L. Wang, B.B. Wu, Y. Fang, B. Xiong, EGCG synergizes the therapeutic effect of cisplatin
922 and oxaliplatin through autophagic pathway in human colorectal cancer cells, *J Pharmacol Sci* 128 (2015)
923 27-34. 10.1016/j.jphs.2015.04.003.

924 [100] A.I. Irimie, C. Braicu, O. Zanoaga, V. Pileczki, C. Gherman, I. Berindan-Neagoe, R.S. Campian,
925 Epigallocatechin-3-gallate suppresses cell proliferation and promotes apoptosis and autophagy in oral
926 cancer SSC-4 cells, *Oncotargets Ther* 8 (2015) 461-470. 10.2147/Ott.S78358.

927 [101] J. Zhou, B.L. Farah, R.A. Sinha, Y. Wu, B.K. Singh, Epigallocatechin-3-Gallate (EGCG), a Green Tea
928 Polyphenol, Stimulates Hepatic Autophagy and Lipid Clearance (vol 9, e87161, 2014), *Plos One* 9 (2014).
929 ARTN e96884
930 10.1371/journal.pone.0096884.

931 [102] A.L. Gray, C.A. Stephens, R.L.H. Bigelow, D.T. Coleman, J.A. Cardelli, The Polyphenols (-)-
932 Epigallocatechin-3-Gallate and Luteolin Synergistically Inhibit TGF-beta-Induced Myofibroblast
933 Phenotypes through RhoA and ERK Inhibition, *Plos One* 9 (2014). ARTN e109208
934 10.1371/journal.pone.0109208.

935 [103] A.P. Chen, L. Zhang, The antioxidant (-)-epigallocatechin-3-gallate inhibits rat hepatic stellate cell
936 proliferation in vitro by blocking the tyrosine phosphorylation and reducing the gene expression of
937 platelet-derived growth factor-beta receptor, *J Biol Chem* 278 (2003) 23381-23389.
938 10.1074/jbc.M212042200.

939 [104] L.L. Chen, Y. Xu, Epigallocatechin gallate attenuates uric acid-induced injury in rat renal interstitial
940 fibroblasts NRK-49F by up-regulation of miR-9, *Eur Rev Med Pharmacol* 22 (2018) 7458-7469.

941 [105] V.M. Adhami, D.N. Syed, N. Khan, H. Mukhtar, Dietary flavonoid fisetin: A novel dual inhibitor of
942 PI3K/Akt and mTOR for prostate cancer management, *Biochem. Pharmacol.* 84 (2012) 1277-1281.
943 10.1016/j.bcp.2012.07.012.

944 [106] X. Sun, X.M. Ma, Q.W. Li, Y. Yang, X.L. Xu, J.Q. Sun, M.W. Yu, K.X. Cao, L. Yang, G.W. Yang, G.L. Zhang,
945 X.M. Wang, Anti-cancer effects of fisetin on mammary carcinoma cells via regulation of the
946 PI3K/Akt/mTOR pathway: In vitro and in vivo studies, *Int J Mol Med* 42 (2018) 811-820.
947 10.3892/ijmm.2018.3654.

948 [107] N. Khan, F. Afaq, F.H. Khusro, V.M. Adhami, Y. Suh, H. Mukhtar, Dual inhibition of
949 phosphatidylinositol 3-kinase/Akt and mammalian target of rapamycin signaling in human nonsmall cell
950 lung cancer cells by a dietary flavonoid fisetin, *Int J Cancer* 130 (2012) 1695-1705. 10.1002/ijc.26178.

951 [108] Y. Suh, F. Afaq, N. Khan, J.J. Johnson, F.H. Khusro, H. Mukhtar, Fisetin induces autophagic cell death
952 through suppression of mTOR signaling pathway in prostate cancer cells, *Carcinogenesis* 31 (2010) 1424-
953 1433. 10.1093/carcin/bgq115.

954 [109] P.M. Yang, H.H. Tseng, C.W. Peng, W.S. Chen, S.J. Chiu, Dietary flavonoid fisetin targets caspase-3-
955 deficient human breast cancer MCF-7 cells by induction of caspase-7-associated apoptosis and inhibition
956 of autophagy, *Int J Oncol* 40 (2012) 469-478. 10.3892/ijo.2011.1203.

957 [110] R.V. Tiwari, P. Parajuli, P.W. Sylvester, gamma-Tocotrienol-induced endoplasmic reticulum stress
958 and autophagy act concurrently to promote breast cancer cell death, *Biochem Cell Biol* 93 (2015) 306-320.
959 10.1139/bcb-2014-0123.

960 [111] S. Deng, M.K. Shanmugam, A.P. Kumar, C.T. Yap, G. Sethi, A. Bishayee, Targeting autophagy using
961 natural compounds for cancer prevention and therapy, *Cancer-Am Cancer Soc* 125 (2019) 1228-1246.
962 10.1002/cncr.31978.

963 [112] Q. Jiang, X.Y. Rao, C.Y. Kim, H. Freiser, Q.B. Zhang, Z.Y. Jiang, G.L. Li, Gamma-tocotrienol induces
964 apoptosis and autophagy in prostate cancer cells by increasing intracellular dihydrosphingosine and
965 dihydroceramide, *Int J Cancer* 130 (2012) 685-693. 10.1002/ijc.26054.

966 [113] R.V. Tiwari, P. Parajuli, P.W. Sylvester, gamma-Tocotrienol-induced autophagy in malignant
967 mammary cancer cells, *Exp Biol Med* 239 (2014) 33-44. 10.1177/1535370213511022.

968 [114] S.H. Kim, E.J. Park, C.R. Lee, J.N. Chun, N.H. Cho, I.G. Kim, S. Lee, T.W. Kim, H.H. Park, I. So, J.H. Jeon,
969 Geraniol induces cooperative interaction of apoptosis and autophagy to elicit cell death in PC-3 prostate
970 cancer cells, *Int J Oncol* 40 (2012) 1683-1690. 10.3892/ijo.2011.1318.

971 [115] L. Trzoss, T. Fukuda, L.V. Costa-Lotufo, P. Jimenez, J.J. La Clair, W. Fenical, Seriniquinone, a selective
972 anticancer agent, induces cell death by autophagocytosis, targeting the cancer-protective protein
973 dermcidin, *P Natl Acad Sci USA* 111 (2014) 14687-14692. 10.1073/pnas.1410932111.

974 [116] S.C. Chu, Y.S. Hsieh, C.C. Yu, Y.Y. Lai, P.N. Chen, Thymoquinone Induces Cell Death in Human
975 Squamous Carcinoma Cells via Caspase Activation-Dependent Apoptosis and LC3-II Activation-Dependent
976 Autophagy, *Plos One* 9 (2014). ARTN e101579
977 10.1371/journal.pone.0101579.

978 [117] I.O. Racoma, W.H. Meisen, Q.E. Wang, B. Kaur, A.A. Wani, Thymoquinone Inhibits Autophagy and
979 Induces Cathepsin-Mediated, Caspase-Independent Cell Death in Glioblastoma Cells, *Plos One* 8 (2013).
980 ARTN e72882

10.1371/journal.pone.0072882.

[118] M.C. Chen, N.H. Lee, H.H. Hsu, T.J. Ho, C.C. Tu, D.J.Y. Hsieh, Y.M. Lin, L.M. Chen, W.W. Kuo, C.Y. Huang, Thymoquinone Induces Caspase-Independent, Autophagic Cell Death in CPT-11-Resistant LoVo Colon Cancer via Mitochondrial Dysfunction and Activation of JNK and p38, *J Agr Food Chem* 63 (2015) 1540-1546. 10.1021/jf5054063.

[119] H.L. Xu, W. Tang, G.H. Du, N. Kokudo, Targeting apoptosis pathways in cancer with magnolol and honokiol, bioactive constituents of the bark of *Magnolia officinalis*, *Drug Discov Ther* 5 (2011) 202-210. 10.5582/ddt.2011.v5.5.202.

[120] H.B. Li, X. Yi, J.M. Gao, X.X. Ying, H.Q. Guan, J.C. Li, Magnolol-induced H460 cells death via autophagy but not apoptosis, *Arch Pharm Res* 30 (2007) 1566-1574. Doi 10.1007/Bf02977326.

[121] A. Rasul, B. Yu, M. Khan, K. Zhang, F. Iqbal, T.H. Ma, H. Yang, Magnolol, a natural compound, induces apoptosis of SGC-7901 human gastric adenocarcinoma cells via the mitochondrial and PI3K/Akt signaling pathways, *Int J Oncol* 40 (2012) 1153-1161. 10.3892/ijo.2011.1277.

[122] U.J. Bae, E.S. Jung, S.J. Jung, S.W. Chae, B.H. Park, Mulberry leaf extract displays antidiabetic activity in db/db mice via Akt and AMP-activated protein kinase phosphorylation, *Food Nutr Res* 62 (2018). ARTN 1473 10.29219/fnr.v62.1473.

[123] K.C. Cheng, C.J. Wang, Y.C. Chang, T.W. Hung, C.J. Lai, C.W. Kuo, H.P. Huang, Mulberry fruits extracts induce apoptosis and autophagy of liver cancer cell and prevent hepatocarcinogenesis in vivo, *J Food Drug Anal* 28 (2020) 84-93. 10.1016/j.jfda.2019.06.002.

[124] Y.H. Kwon, K. Bishayee, M.A. Rahman, J.S. Hong, S.S. Lim, S.O. Huh, *Morus alba* Accumulates Reactive Oxygen Species to Initiate Apoptosis via FOXO-Caspase 3-Dependent Pathway in Neuroblastoma Cells, *Mol Cells* 38 (2015) 630-637. 10.14348/molcells.2015.0030.

[125] Y.Z. Lao, G. Wan, Z.Y. Liu, X.Y. Wang, P. Ruan, W. Xu, D.Q. Xu, W.D. Xie, Y. Zhang, H.X. Xu, N.H. Xu, The natural compound oblongifolin C inhibits autophagic flux and enhances antitumor efficacy of nutrient deprivation, *Autophagy* 10 (2014) 736-749. 10.4161/auto.28034.

[126] M. Wu, Y.Z. Lao, H.S. Tan, G. Lu, Y. Ren, Z.Q. Zheng, J. Yi, W.W. Fu, H.M. Shen, H.X. Xu, Oblongifolin C suppresses lysosomal function independently of TFEB nuclear translocation, *Acta Pharmacol Sin* 40 (2019) 929-937. 10.1038/s41401-018-0167-7.

[127] B.R. Acharya, S. Bhattacharyya, D. Choudhury, G. Chakrabarti, The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung cancer cells, *Apoptosis* 16 (2011) 924-939. 10.1007/s10495-011-0613-1.

[128] I. Herr, V. Lozanovski, P. Houben, P. Schemmer, M.W. Buchler, Sulforaphane and related mustard oils in focus of cancer prevention and therapy, *Wien Med Wochenschr* 163 (2013) 80-88. 10.1007/s10354-012-0163-3.

[129] A. Herman-Antosiewicz, D.E. Johnson, S.V. Singh, Sulforaphane causes autophagy to inhibit release of cytochrome C and apoptosis in human prostate cancer cells, *Cancer Res* 66 (2006) 5828-5835. 10.1158/0008-5472.CAN-06-0139.

[130] Z. Zheng, K. Lin, Y. Hu, Y. Zhou, X. Ding, Y. Wang, W. Wu, Sulforaphane metabolites inhibit migration and invasion via microtubule-mediated Claudins dysfunction or inhibition of autolysosome formation in human non-small cell lung cancer cells, *Cell Death Dis* 10 (2019) 259. 10.1038/s41419-019-1489-1.

[131] D. Chaudhuri, S. Orsulic, B.T. Ashok, Antiproliferative activity of sulforaphane in Akt-overexpressing ovarian cancer cells, *Mol Cancer Ther* 6 (2007) 334-345. 10.1158/1535-7163.MCT-06-0404.

[132] M.S. Uddin, A.A. Mamun, M. Jakaria, S. Thangapandian, J. Ahmad, M.A. Rahman, B. Mathew, M.M. Abdel-Daim, L. Aleya, Emerging promise of sulforaphane-mediated Nrf2 signaling cascade against neurological disorders, *Sci Total Environ* 707 (2020) 135624. 10.1016/j.scitotenv.2019.135624.

1027 [133] S.M. Kim, H.S. Park, D.Y. Jun, H.J. Woo, M.H. Woo, C.H. Yang, Y.H. Kim, Mollugin induces apoptosis
1028 in human Jurkat T cells through endoplasmic reticulum stress-mediated activation of JNK and caspase-12
1029 and subsequent activation of mitochondria-dependent caspase cascade regulated by Bcl-xL, Toxicol Appl
1030 Pharm 241 (2009) 210-220. 10.1016/j.taap.2009.08.024.

1031 [134] L. Zhang, H.D. Wang, J.H. Zhu, J.G. Xu, K. Ding, Mollugin induces tumor cell apoptosis and autophagy
1032 via the PI3K/AKT/mTOR/p70S6K and ERK signaling pathways, Biochem Bioph Res Co 450 (2014) 247-254.
1033 10.1016/j.bbrc.2014.05.101.

1034 [135] M.Y. Xu, S.Y. Lee, S.S. Kang, Y.S. Kim, Antitumor Activity of Jujuboside B and the Underlying
1035 Mechanism via Induction of Apoptosis and Autophagy, J Nat Prod 77 (2014) 370-376. 10.1021/np401022g.

1036 [136] J. Lu, D.P. Sun, S. Gao, Y. Gao, J.T. Ye, P.Q. Liu, Cyclovirobuxine D Induces Autophagy-Associated Cell
1037 Death via the Akt/mTOR Pathway in MCF-7 Human Breast Cancer Cells, J Pharmacol Sci 125 (2014) 74-82.
1038 10.1254/jphs.14013FP.

1039 [137] L. Ouyang, Y. Chen, X.Y. Wang, R.F. Lu, S.Y. Zhang, M. Tian, T. Xie, B. Liu, G. He, Polygonatum
1040 odoratum lectin induces apoptosis and autophagy via targeting EGFR-mediated Ras-Raf-MEK-ERK
1041 pathway in human MCF-7 breast cancer cells, Phytomedicine 21 (2014) 1658-1665.
1042 10.1016/j.phymed.2014.08.002.

1043 [138] C.Y. Li, J. Chen, B.M. Lu, Z. Shi, H.L. Wang, B. Zhang, K.L. Zhao, W. Qi, J.K. Bao, Y. Wang, Molecular
1044 Switch Role of Akt in Polygonatum odoratum Lectin-Induced Apoptosis and Autophagy in Human Non-
1045 Small Cell Lung Cancer A549 Cells, Plos One 9 (2014). ARTN e101526
1046 10.1371/journal.pone.0101526.

1047 [139] H. Jiang, L. Zhang, J. Kuo, K. Kuo, S.C. Gautam, L. Groc, A.I. Rodriguez, D. Koubi, T.J. Hunter, G.B.
1048 Corcoran, M.D. Seidman, R.A. Levine, Resveratrol-induced apoptotic death in human U251 glioma cells,
1049 Mol Cancer Ther 4 (2005) 554-561. Doi 10.1158/1535-7163.Mct-04-0056.

1050 [140] M.A. Rahman, N.H. Kim, S.H. Kim, S.M. Oh, S.O. Huh, Antiproliferative and Cytotoxic Effects of
1051 Resveratrol in Mitochondria-Mediated Apoptosis in Rat B103 Neuroblastoma Cells, Korean J Physiol Pha
1052 16 (2012) 321-326. 10.4196/kjpp.2012.16.5.321.

1053 [141] F.F. Lang, Z.Y. Qin, F. Li, H.L. Zhang, Z.H. Fang, E.K. Hao, Apoptotic Cell Death Induced by Resveratrol
1054 Is Partially Mediated by the Autophagy Pathway in Human Ovarian Cancer Cells, Plos One 10 (2015). UNSP
1055 e0129196
1056 10.1371/journal.pone.0129196.

1057 [142] T. Garg, V.K. Yadav, Effects of Resveratrol as an anticancer agent. A Systematic Review and Meta-
1058 Analysis, Indian J Pharmacol 45 (2013) S206-S206.

1059 [143] C.H. Gong, H.L. Xia, Resveratrol suppresses melanoma growth by promoting autophagy through
1060 inhibiting the PI3K/AKT/mTOR signaling pathway, Exp Ther Med 19 (2020) 1878-1886.
1061 10.3892/etm.2019.8359.

1062 [144] Q.J. Liu, Q. Fang, S.Q. Ji, Z.X. Han, W.L. Cheng, H.J. Zhang, Resveratrol-mediated apoptosis in renal
1063 cell carcinoma via the p53/AMP-activated protein kinase/mammalian target of rapamycin autophagy
1064 signaling pathway, Mol Med Rep 17 (2018) 502-508. 10.3892/mmr.2017.7868.

1065 [145] S. Godichaud, K. Si-Tayeb, N. Auge, A. Desmouliere, C. Balabaud, B. Payraastre, A. Negre-Salvayre, J.
1066 Rosenbaum, The grape-derived polyphenol resveratrol differentially affects epidermal and platelet-
1067 derived growth factor signaling in human liver myofibroblasts, Int J Biochem Cell B 38 (2006) 629-637.
1068 10.1016/j.biocel.2005.11.001.

1069 [146] Y.D. Jiang, L. Liu, J.J. Steinle, miRNA15a regulates insulin signal transduction in the retinal vasculature,
1070 Cell. Signal. 44 (2018) 28-32. 10.1016/j.cellsig.2018.01.016.

1071 [147] A.V. Anand David, R. Arulmoli, S. Parasuraman, Overviews of Biological Importance of Quercetin: A
1072 Bioactive Flavonoid, Pharmacogn Rev 10 (2016) 84-89. 10.4103/0973-7847.194044.

[148] B.N. Singh, D. Kumar, S. Shankar, R.K. Srivastava, Rottlerin induces autophagy which leads to apoptotic cell death through inhibition of PI3K/Akt/mTOR pathway in human pancreatic cancer stem cells, *Biochem. Pharmacol.* 84 (2012) 1154-1163. 10.1016/j.bcp.2012.08.007.

[149] M.A. Rahman, N.H. Kim, H. Yang, S.O. Huh, Angelicin induces apoptosis through intrinsic caspase-dependent pathway in human SH-SY5Y neuroblastoma cells, *Mol. Cell. Biochem.* 369 (2012) 95-104. 10.1007/s11010-012-1372-1.

[150] M.A. Rahman, K. Bishayee, S.O. Huh, Angelica polymorpha Maxim Induces Apoptosis of Human SH-SY5Y Neuroblastoma Cells by Regulating an Intrinsic Caspase Pathway, *Mol Cells* 39 (2016) 119-128. 10.14348/molcells.2016.2232.

[151] Y.R. Wang, Y.Q. Chen, X.D. Chen, Y. Liang, D.P. Yang, J. Dong, N. Yang, Z.Q. Liang, Angelicin inhibits the malignant behaviours of human cervical cancer potentially via inhibiting autophagy, *Exp Ther Med* 18 (2019) 3365-3374. 10.3892/etm.2019.7985.

[152] M.S. Uddin, M.A. Rahman, M.T. Kabir, T. Behl, B. Mathew, A. Perveen, G.E. Barreto, M.N. Bin-Jumah, M.M. Abdel-Daim, G.M. Ashraf, Multifarious roles of mTOR signaling in cognitive aging and cerebrovascular dysfunction of Alzheimer's disease, *lubmb Life* (2020). 10.1002/iub.2324.

[153] S. Leng, Y. Hao, D. Du, S. Xie, L. Hong, H. Gu, X. Zhu, J. Zhang, D. Fan, H.F. Kung, Ursolic acid promotes cancer cell death by inducing Atg5-dependent autophagy, *Int J Cancer* 133 (2013) 2781-2790. 10.1002/ijc.28301.

[154] C.P.R. Xavier, C.F. Lima, D.F.N. Pedro, J.M. Wilson, K. Kristiansen, C. Pereira-Wilson, Ursolic acid induces cell death and modulates autophagy through JNK pathway in apoptosis-resistant colorectal cancer cells, *J Nutr Biochem* 24 (2013) 706-712. 10.1016/j.jnutbio.2012.04.004.

[155] C. Zhao, S.T. Yin, Y.H. Dong, X. Guo, L.H. Fan, M. Ye, H.B. Hu, Autophagy-dependent EIF2AK3 activation compromises ursolic acid-induced apoptosis through upregulation of MCL1 in MCF-7 human breast cancer cells, *Autophagy* 9 (2013) 196-207. 10.4161/auto.22805.

[156] S.W. Shin, J.W. Park, Autophagy inhibition enhances ursolic acid-induced apoptosis in PC3 cells, *Free Radical Bio Med* 53 (2012) S116-S116. 10.1016/j.freeradbiomed.2012.08.242.

[157] S.Y. Wang, Q.J. Yu, J.K. Bao, B. Liu, Polygonatum cyrtonema lectin, a potential antineoplastic drug targeting programmed cell death pathways, *Biochem Bioph Res Co* 406 (2011) 497-500. 10.1016/j.bbrc.2011.02.049.

[158] B. Liu, Y. Cheng, H.J. Bian, J.K. Bao, Molecular mechanisms of Polygonatum cyrtonema lectin-induced apoptosis and autophagy in cancer cells, *Autophagy* 5 (2009) 253-255. DOI 10.4161/auto.5.2.7561.

[159] B. Liu, Y. Cheng, B. Zhang, H.J. Bian, J.K. Bao, Polygonatum cyrtonema lectin induces apoptosis and autophagy in human melanoma A375 cells through a mitochondria-mediated ROS-p38-p53 pathway, *Cancer Letters* 275 (2009) 54-60. 10.1016/j.canlet.2008.09.042.

[160] W.J. Duan, Q.S. Li, M.Y. Xia, S.I. Tashiro, S. Onodera, T. Ikejima, Silibinin Activated p53 and Induced Autophagic Death in Human Fibrosarcoma HT1080 Cells via Reactive Oxygen Species-p38 and c-Jun N-Terminal Kinase Pathways, *Biol Pharm Bull* 34 (2011) 47-53. DOI 10.1248/bpb.34.47.

[161] M.A. Rahman, H. Yang, N.H. Kim, S.O. Huh, Induction of apoptosis by Dioscorea nipponica Makino extracts in human SH-SY5Y neuroblastoma cells via mitochondria-mediated pathway, *Anim Cells Syst* 18 (2014) 41-51. 10.1080/19768354.2014.880372.

[162] M.A. Rahman, H. Yang, S.S. Lim, S.O. Huh, Apoptotic Effects of Melandryum firmum Root Extracts in Human SH-SY5Y Neuroblastoma Cells, *Exp Neurobiol* 22 (2013) 208-213. 10.5607/en.2013.22.3.208.

[163] D.C. Bassham, J.L. Crespo, Autophagy in plants and algae, *Front Plant Sci* 5 (2014). ARTN 679 10.3389/fpls.2014.00679.

[164] M.S. Uddin, A.A. Mamun, M.A. Rahman, M.T. Kabir, S. Alkahtani, I.S. Alanazi, A. Perveen, G.M. Ashraf, M.N. Bin-Jumah, M.M. Abdel-Daim, Exploring the Promise of Flavonoids to Combat Neuropathic Pain:

1119 From Molecular Mechanisms to Therapeutic Implications, *Front Neurosci* 14 (2020) 478.
 1120 10.3389/fnins.2020.00478.

1121 [165] M.A. Rahman, J.S. Hong, S.O. Huh, Antiproliferative properties of *Saussurea lappa* Clarke root extract
 1122 in SH-SY5Y neuroblastoma cells via intrinsic apoptotic pathway, *Anim Cells Syst* 19 (2015) 119-126.
 1123 10.1080/19768354.2015.1008041.

1124 [166] X. Tian, H.S. Song, Y.M. Cho, B. Park, Y.J. Song, S. Jang, S.C. Kang, Anticancer effect of *Saussurea*
 1125 *lappa* extract via dual control of apoptosis and autophagy in prostate cancer cells, *Medicine* 96 (2017).
 1126 ARTN e7606
 1127 10.1097/MD.0000000000007606.

1128 [167] N. Ryoo, M.A. Rahman, H. Hwang, S.K. Ko, S.Y. Nah, H.C. Kim, H. Rhim, Ginsenoside Rk1 is a novel
 1129 inhibitor of NMDA receptors in cultured rat hippocampal neurons, *Journal of Ginseng Research* 44 (2020)
 1130 490-495. 10.1016/j.jgr.2019.04.002.

1131 [168] H. Ko, Y.J. Kim, J.S. Park, J.H. Park, H.O. Yang, Autophagy Inhibition Enhances Apoptosis Induced by
 1132 Ginsenoside Rk1 in Hepatocellular Carcinoma Cells, *Biosci Biotech Bioch* 73 (2009) 2183-2189.
 1133 10.1271/bbb.90250.

1134 [169] S. Zecchini, F.P. Serafini, E. Catalani, M. Giovarelli, M. Coazzoli, I. Di Renzo, C. De Palma, C. Perrotta,
 1135 E. Clementi, F. Buonanno, C. Ortenzi, E. Marcantoni, A.R. Taddei, S. Picchietti, A.M. Fausto, D. Cervia,
 1136 Dysfunctional autophagy induced by the pro-apoptotic natural compound climacostol in tumour cells, *Cell*
 1137 *Death Dis* 10 (2018). ARTN 10
 1138 10.1038/s41419-018-1254-x.

1139 [170] S. Saha, D.P. Panigrahi, S. Patil, S.K. Bhutia, Autophagy in health and disease: A comprehensive
 1140 review, *Biomedicine & Pharmacotherapy* 104 (2018) 485-495. 10.1016/j.biopha.2018.05.007.

1141 [171] C. Grossi, S. Rigacci, S. Ambrosini, T. Ed Dami, I. Luccarini, C. Traini, P. Failli, A. Berti, F. Casamenti,
 1142 M. Stefani, The polyphenol oleuropein aglycone protects TgCRND8 mice against Ass plaque pathology,
 1143 *PLoS One* 8 (2013) e71702. 10.1371/journal.pone.0071702.

1144 [172] I. Luccarini, C. Grossi, S. Rigacci, E. Coppi, A.M. Pugliese, D. Pantano, G. la Marca, T. Ed Dami, A. Berti,
 1145 M. Stefani, F. Casamenti, Oleuropein aglycone protects against pyroglutamylation-3 amyloid-ss toxicity:
 1146 biochemical, epigenetic and functional correlates, *Neurobiol Aging* 36 (2015) 648-663.
 1147 10.1016/j.neurobiolaging.2014.08.029.

1148 [173] Z. Zhu, J. Yan, W. Jiang, X.G. Yao, J. Chen, L. Chen, C. Li, L. Hu, H. Jiang, X. Shen, Arctigenin effectively
 1149 ameliorates memory impairment in Alzheimer's disease model mice targeting both beta-amyloid
 1150 production and clearance, *J Neurosci* 33 (2013) 13138-13149. 10.1523/JNEUROSCI.4790-12.2013.

1151 [174] C. Lu, Y. Guo, J. Yan, Z. Luo, H.B. Luo, M. Yan, L. Huang, X. Li, Design, synthesis, and evaluation of
 1152 multitarget-directed resveratrol derivatives for the treatment of Alzheimer's disease, *J Med Chem* 56
 1153 (2013) 5843-5859. 10.1021/jm400567s.

1154 [175] M.R. de Oliveira, S.F. Nabavi, A. Manayi, M. Daglia, Z. Hajheydari, S.M. Nabavi, Resveratrol and the
 1155 mitochondria: From triggering the intrinsic apoptotic pathway to inducing mitochondrial biogenesis, a
 1156 mechanistic view, *Bba-Gen Subjects* 1860 (2016) 727-745. 10.1016/j.bbagen.2016.01.017.

1157 [176] B. Juhasz, B. Varga, R. Gesztelyi, A. Kemeny-Beke, J. Zsuga, A. Tosaki, Resveratrol: A Multifunctional
 1158 Cytoprotective Molecule, *Curr Pharm Biotechno* 11 (2010) 810-818. Doi 10.2174/138920110793262079.

1159 [177] G. Filomeni, I. Graziani, D. De Zio, L. Dini, D. Centonze, G. Rotilio, M.R. Ciriolo, Neuroprotection of
 1160 kaempferol by autophagy in models of rotenone-mediated acute toxicity: possible implications for
 1161 Parkinson's disease, *Neurobiol Aging* 33 (2012) 767-785. 10.1016/j.neurobiolaging.2010.05.021.

1162 [178] J.H. Lu, J.Q. Tan, S.S. Durairajan, L.F. Liu, Z.H. Zhang, L. Ma, H.M. Shen, H.Y. Chan, M. Li,
 1163 Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via
 1164 inducing autophagy, *Autophagy* 8 (2012) 98-108. 10.4161/auto.8.1.18313.

1165 [179] Y. Sasazawa, N. Sato, K. Umezawa, S. Simizu, Conophylline protects cells in cellular models of
 1166 neurodegenerative diseases by inducing mammalian target of rapamycin (mTOR)-independent autophagy,
 1167 J Biol Chem 290 (2015) 6168-6178. 10.1074/jbc.M114.606293.
 1168 [180] T.F. Jiang, Y.J. Zhang, H.Y. Zhou, H.M. Wang, L.P. Tian, J. Liu, J.Q. Ding, S.D. Chen, Curcumin
 1169 ameliorates the neurodegenerative pathology in A53T alpha-synuclein cell model of Parkinson's disease
 1170 through the downregulation of mTOR/p70S6K signaling and the recovery of macroautophagy, J
 1171 Neuroimmune Pharmacol 8 (2013) 356-369. 10.1007/s11481-012-9431-7.
 1172 [181] Y.J. Guo, S.Y. Dong, X.X. Cui, Y. Feng, T. Liu, M. Yin, S.H. Kuo, E.K. Tan, W.J. Zhao, Y.C. Wu, Resveratrol
 1173 alleviates MPTP-induced motor impairments and pathological changes by autophagic degradation of
 1174 alpha-synuclein via SIRT1-deacetylated LC3, Mol Nutr Food Res 60 (2016) 2161-2175.
 1175 10.1002/mnfr.201600111.
 1176 [182] A. Ferretta, A. Gaballo, P. Tanzarella, C. Piccoli, N. Capitanio, B. Nico, T. Annese, M. Di Paola, C.
 1177 Dell'aquila, M. De Mari, E. Ferranini, V. Bonifati, C. Pacelli, T. Cocco, Effect of resveratrol on mitochondrial
 1178 function: implications in parkin-associated familial Parkinson's disease, Biochim Biophys Acta 1842 (2014)
 1179 902-915. 10.1016/j.bbadis.2014.02.010.
 1180 [183] C.Z. Cai, H.F. Zhou, N.N. Yuan, M.Y. Wu, S.M. Lee, J.Y. Ren, H.X. Su, J.J. Lu, X.P. Chen, M. Li, J.Q. Tan,
 1181 J.H. Lu, Natural alkaloid harmine promotes degradation of alpha-synuclein via PKA-mediated ubiquitin-
 1182 proteasome system activation, Phytomedicine 61 (2019) 152842. 10.1016/j.phymed.2019.152842.
 1183 [184] V.K. Wong, A.G. Wu, J.R. Wang, L. Liu, B.Y. Law, Neferine attenuates the protein level and toxicity of
 1184 mutant huntingtin in PC-12 cells via induction of autophagy, Molecules 20 (2015) 3496-3514.
 1185 10.3390/molecules20033496.
 1186 [185] S. Sarkar, J.E. Davies, Z. Huang, A. Tunnacliffe, D.C. Rubinsztein, Trehalose, a novel mTOR-
 1187 independent autophagy enhancer, accelerates the clearance of mutant huntingtin and alpha-synuclein, J
 1188 Biol Chem 282 (2007) 5641-5652. 10.1074/jbc.M609532200.
 1189 [186] W. Jiang, W. Wei, M.A. Gaertig, S. Li, X.J. Li, Therapeutic Effect of Berberine on Huntington's Disease
 1190 Transgenic Mouse Model, PLoS One 10 (2015) e0134142. 10.1371/journal.pone.0134142.
 1191 [187] K. Castillo, M. Nassif, V. Valenzuela, F. Rojas, S. Matus, G. Mercado, F.A. Court, B. van Zundert, C.
 1192 Hetz, Trehalose delays the progression of amyotrophic lateral sclerosis by enhancing autophagy in
 1193 motoneurons, Autophagy 9 (2013) 1308-1320. 10.4161/auto.25188.
 1194 [188] F.M. Menzies, J. Huebener, M. Renna, M. Bonin, O. Riess, D.C. Rubinsztein, Autophagy induction
 1195 reduces mutant ataxin-3 levels and toxicity in a mouse model of spinocerebellar ataxia type 3, Brain 133
 1196 (2010) 93-104. 10.1093/brain/awp292.
 1197 [189] J. Singhal, L.D. Nagaprashantha, R. Vatsyayan, Ashutosh, S. Awasthi, S.S. Singhal, Didymine induces
 1198 apoptosis by inhibiting N-Myc and upregulating RKIP in neuroblastoma, Cancer Prev Res (Phila) 5 (2012)
 1199 473-483. 10.1158/1940-6207.CAPR-11-0318.
 1200 [190] M.A. Rahman, N.H. Kim, S.O. Huh, Cytotoxic effect of gambogic acid on SH-SY5Y neuroblastoma cells
 1201 is mediated by intrinsic caspase-dependent signaling pathway, Mol Cell Biochem 377 (2013) 187-196.
 1202 10.1007/s11010-013-1584-z.
 1203 [191] R. Vengoji, M.A. Macha, S.K. Batra, N.A. Shonka, Natural products: a hope for glioblastoma patients,
 1204 Oncotarget 9 (2018) 22194-22219. 10.18632/oncotarget.25175.
 1205 [192] Y. Yuan, X. Xue, R.B. Guo, X.L. Sun, G. Hu, Resveratrol Enhances the Antitumor Effects of
 1206 Temozolomide in Glioblastoma via ROS-dependent AMPK-TSC-mTOR Signaling Pathway, Cns Neurosci
 1207 Ther 18 (2012) 536-546. 10.1111/j.1755-5949.2012.00319.x.
 1208 [193] S.H. Shah, Carbonic anhydrase, net photosynthetic rate and yield of black cumin (*Nigella sativa*)
 1209 plants sprayed with kinetin, Acta Bot. Croat. 67 (2008) 63-68.

1210 [194] A.R. Hussain, S. Uddin, M. Ahmed, F. Al-Dayel, P.P. Bavi, K.S. Al-Kuraya, Phosphorylated
 1211 IkappaBalpha predicts poor prognosis in activated B-cell lymphoma and its inhibition with thymoquinone
 1212 induces apoptosis via ROS release, *Plos One* 8 (2013) e60540. 10.1371/journal.pone.0060540.

1213 [195] K. Yamamoto, C. Ishikawa, H. Katano, T. Yasumoto, N. Mori, Fucoxanthin and its deacetylated
 1214 product, fucoxanthinol, induce apoptosis of primary effusion lymphomas, *Cancer Lett* 300 (2011) 225-234.
 1215 10.1016/j.canlet.2010.10.016.

1216 [196] Q. Zhao, J.W. Guan, Y.H. Qin, P. Ren, Z.W. Zhang, J. Lv, S.J. Sun, C.L. Zhang, W.F. Mao, Curcumin
 1217 sensitizes lymphoma cells to DNA damage agents through regulating Rad51-dependent homologous
 1218 recombination, *Biomedicine & Pharmacotherapy* 97 (2018) 115-119. 10.1016/j.biopha.2017.09.078.

1219 [197] L.Y. Shi, H.H. Qin, X.D. Jin, X.X. Yang, X. Lu, H.G. Wang, R.Y. Wang, D.Y. Yu, B.M. Feng, The natural
 1220 phenolic peperobtusin A induces apoptosis of lymphoma U937 cells via the Caspase dependent and p38
 1221 MAPK signaling pathways, *Biomedicine & Pharmacotherapy* 102 (2018) 772-781.
 1222 10.1016/j.biopha.2018.03.141.

1223 [198] X.H. Xiao, H.L. Li, H.Z. Jin, J. Jin, M. Yu, C.M. Ma, Y. Tong, L. Zhou, H. Lei, H.Z. Xu, W.D. Zhang, W. Liu,
 1224 Y.L. Wu, Identification of 11(13)-dehydroivaxillin as a potent therapeutic agent against non-Hodgkin's
 1225 lymphoma, *Cell Death Dis* 8 (2017). ARTN e3050
 1226 10.1038/cddis.2017.442.

1227 [199] R. Martino, M.F. Beer, O. Elso, O. Donadel, V. Sulsen, C. Anesini, Sesquiterpene lactones from
 1228 *Ambrosia* spp. are active against a murine lymphoma cell line by inducing apoptosis and cell cycle arrest,
 1229 *Toxicol. Vitro* 29 (2015) 1529-1536. 10.1016/j.tiv.2015.06.011.

1230 [200] A.M. Leidal, B. Levine, J. Debnath, Autophagy and the cell biology of age-related disease, *Nat Cell*
 1231 *Biol* 20 (2018) 1338-1348. 10.1038/s41556-018-0235-8.

1232 [201] S. Sciarretta, Y. Maejima, D. Zablocki, J. Sadoshima, The Role of Autophagy in the Heart, *Annu Rev*
 1233 *Physiol* 80 (2018) 1-26. 10.1146/annurev-physiol-021317-121427.

1234 [202] G. Meyer, A. Czompa, C. Reboul, E. Csepanyi, A. Czeglédi, I. Bak, G. Balla, J. Balla, A. Tosaki, I. Lekli,
 1235 The cellular autophagy markers Beclin-1 and LC3B-II are increased during reperfusion in fibrillated mouse
 1236 hearts, *Curr Pharm Des* 19 (2013) 6912-6918. 10.2174/138161281939131127122510.

1237 [203] A. Shirakabe, P. Zhai, Y. Ikeda, T. Saito, Y. Maejima, C.P. Hsu, M. Nomura, K. Egashira, B. Levine, J.
 1238 Sadoshima, Drp1-Dependent Mitochondrial Autophagy Plays a Protective Role Against Pressure Overload-
 1239 Induced Mitochondrial Dysfunction and Heart Failure, *Circulation* 133 (2016) 1249-1263.
 1240 10.1161/CIRCULATIONAHA.115.020502.

1241 [204] Y. Matsui, H. Takagi, X.P. Qu, M. Abdellatif, H. Sakoda, T. Asano, B. Levine, J. Sadoshima, Distinct
 1242 roles of autophagy in the heart during ischemia and reperfusion - Roles of AMP-activated protein kinase
 1243 and Beclin 1 in mediating autophagy, *Circ Res* 100 (2007) 914-922. 10.1161/01.Res.0000261924.76669.36.

1244 [205] Y. Sun, X. Yao, Q.J. Zhang, M. Zhu, Z.P. Liu, B. Ci, Y. Xie, D. Carlson, B.A. Rothermel, Y. Sun, B. Levine,
 1245 J.A. Hill, S.E. Wolf, J.P. Minei, Q.S. Zang, Beclin-1-Dependent Autophagy Protects the Heart During Sepsis,
 1246 *Circulation* 138 (2018) 2247-2262. 10.1161/CIRCULATIONAHA.117.032821.

1247 [206] A. Gyongyosi, K. Szoke, F. Fenyvesi, Z. Fejes, I.B. Debreceni, B. Nagy, A. Tosaki, I. Lekli, Inhibited
 1248 autophagy may contribute to heme toxicity in cardiomyoblast cells, *Biochem Bioph Res Co* 511 (2019)
 1249 732-738. 10.1016/j.bbrc.2019.02.140.

1250 [207] Y.T. Zheng, B.H. Shi, M.Q. Ma, X.Q. Wu, X.H. Lin, The novel relationship between Sirt3 and autophagy
 1251 in myocardial ischemia-reperfusion, *J Cell Physiol* 234 (2019) 5488-5495. 10.1002/jcp.27329.

1252 [208] R. Zilinyi, A. Czompa, A. Czeglédi, A. Gajtko, D. Pituk, I. Lekli, A. Tosaki, The Cardioprotective Effect
 1253 of Metformin in Doxorubicin-Induced Cardiotoxicity: The Role of Autophagy, *Molecules* 23 (2018).
 1254 10.3390/molecules23051184.

1255 [209] A. Gyongyosi, R. Zilinyi, A. Czegledi, A. Tosaki, A. Tosaki, I. Lekli, The Role of Autophagy and Death
 1256 Pathways in Dose-dependent Isoproterenolinduced Cardiotoxicity, *Curr Pharm Des* 25 (2019) 2192-2198.
 1257 10.2174/1381612825666190619145025.
 1258 [210] Y. Dong, H.W. Chen, J.L. Gao, Y.M. Liu, J. Li, J. Wang, Molecular machinery and interplay of apoptosis
 1259 and autophagy in coronary heart disease, *J Mol Cell Cardiol* 136 (2019) 27-41.
 1260 10.1016/j.yjmcc.2019.09.001.
 1261 [211] I. Lekli, D.D. Haines, G. Balla, A. Tosaki, Autophagy: an adaptive physiological countermeasure to
 1262 cellular senescence and ischaemia/reperfusion-associated cardiac arrhythmias, *J Cell Mol Med* 21 (2017)
 1263 1058-1072. 10.1111/jcmm.13053.
 1264 [212] M.A. Rahman, S.K. Saha, M.S. Rahman, M.J. Uddin, M.S. Uddin, M.G. Pang, H. Rhim, S.G. Cho,
 1265 Molecular Insights Into Therapeutic Potential of Autophagy Modulation by Natural Products for Cancer
 1266 Stem Cells, *Front Cell Dev Biol* 8 (2020). ARTN 283
 1267 10.3389/fcell.2020.00283.
 1268 [213] E.J. Sohn, H.T. Park, Natural agents mediated autophagic signal networks in cancer, *Cancer Cell Int.*
 1269 17 (2017). ARTN 110
 1270 10.1186/s12935-017-0486-7.
 1271